Alnylam Pharmaceuticals, Inc
(NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, an...

Website: http://www.alnylam.com

Founded: 2002

Full Time Employees: 1,323

Sector: Healthcare

Industry: Biotechnology

Pharmaceuticals

Share this website to your friends

• Market Cap:

• Exchange:

• Shs Outstanding:

• Employees:

• Beta:

• Return on Equity (ROE) ttm:

• Return on Assets (ROA) ttm:

• EPS ttm:

• Book value per Share:

• Cash per Share:

• Current ast per Share:

• P/E ttm:

• P/E forward:

• P/E ttm high:

• P/E ttm low:

• P/S ttm:

• P/B ttm:

• P/FCF ttm:

• PEG ratio:

• Cash Ratio ttm:

• Quick Ratio ttm:

• Current Ratio ttm:

• Gross Mgn ttm:

• EBITDA Mgn ttm:

• Operating Mgn ttm:

• Net Income Mgn ttm:

• Trailing Div yield:

• Forward Div yield:

• Payout Ratio ttm:

• Ex-Dividend date:

• Target Price High:

• Target Price Low:

• Target Price Mean:

• Number of Analysts:

• Debt Ratio ttm:

• Debt to Equity ttm:

• Total Net Debt:

At a glance:

Bull Thesis:

Bear Thesis:

Main Competitors:

Moat:

Income Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30

statements of operations
revenues:
net product revenues	1,036,127,000	994,717,000	851,082,000	672,212,000	468,538,000	450,831,000	420,146,000	410,088,000	365,163,000	346,288,000	313,153,000	305,705,000	276,328,000	261,675,000	232,267,000	213,515,000	186,872,000	198,514,000	167,044,000	160,811,000	135,769,000	112,843,000	99,206,000	77,533,000	71,938,000
net revenues from collaborations	82,075,000	40,943,000	351,742,000	61,496,000	99,185,000	106,948,000	57,387,000	227,338,000	118,548,000	76,407,000	427,472,000	5,844,000	36,462,000	70,645,000	29,297,000	9,025,000	25,945,000	59,625,000	20,136,000	59,395,000	41,797,000	50,719,000	26,647,000	26,429,000	27,538,000
royalty revenue	48,973,000	61,373,000	46,202,000	39,981,000	26,466,000	35,387,000	23,386,000	22,399,000	10,622,000	17,023,000	9,905,000	7,205,000	6,500,000	2,715,000	2,742,000	2,278,000	442,000	396,000	453,000	347,000
total revenues	1,167,175,000	1,097,033,000	1,249,026,000	773,689,000	594,189,000	593,166,000	500,919,000	659,825,000	494,333,000	439,718,000	750,530,000	318,754,000	319,290,000	335,035,000	264,306,000	224,818,000	213,259,000	258,535,000	187,633,000	220,553,000	177,566,000	163,562,000	125,853,000	103,962,000	99,476,000	71,681,000	70,061,000	44,714,000	33,294,000	21,033,000	2,069,000
yoy	96.43%	84.95%	149.35%	17.26%	20.20%	34.90%	-33.26%	107.00%	54.82%	31.25%	183.96%	41.78%	49.72%	29.59%	40.86%	1.93%	20.10%	58.07%	49.09%	112.15%	78.50%	128.18%	79.63%	132.50%	198.78%	240.80%	3286.23%
qoq	6.39%	-12.17%	61.44%	30.21%	0.17%	18.42%	-24.08%	33.48%	12.42%	-41.41%	135.46%	-0.17%	-4.70%	26.76%	17.56%	5.42%	-17.51%	37.79%	-14.93%	24.21%	8.56%	29.96%	21.06%	4.51%	38.78%	2.31%	56.69%	34.30%	58.29%	916.58%
operating costs and expenses:
cost of goods sold	207,520,000	267,723,000	197,231,000	142,029,000	70,183,000	102,649,000	81,980,000	67,271,000	54,613,000	71,975,000	79,473,000	75,336,000	41,432,000	46,172,000	36,507,000	34,038,000	23,457,000	33,635,000	28,091,000	30,256,000	23,023,000	23,024,000	21,797,000	19,929,000	13,302,000	12,176,000	5,213,000	4,326,000	3,347,000	1,665,000	137,000
gross profit	959,655,000	829,310,000	1,051,795,000	631,660,000	524,006,000	490,517,000	418,939,000	592,554,000	439,720,000	367,743,000	671,057,000	243,418,000	277,858,000	288,863,000	227,799,000	190,780,000	189,802,000	224,900,000	159,542,000	190,297,000	154,543,000	140,538,000	104,056,000	84,033,000	86,174,000	59,505,000	64,848,000	40,388,000	29,947,000	19,368,000	1,932,000
yoy	83.14%	69.07%	151.06%	6.60%	19.17%	33.39%	-37.57%	143.43%	58.25%	27.31%	194.58%	27.59%	46.39%	28.44%	42.78%	0.25%	22.82%	60.03%	53.32%	126.46%	79.34%	136.18%	60.46%	108.06%	187.76%	207.23%	3256.52%
qoq	15.72%	-21.15%	66.51%	20.54%	6.83%	17.09%	-29.30%	34.76%	19.57%	-45.20%	175.68%	-12.39%	-3.81%	26.81%	19.40%	0.52%	-15.61%	40.97%	-16.16%	23.14%	9.97%	35.06%	23.83%	-2.48%	44.82%	-8.24%	60.56%	34.86%	54.62%	902.48%
gross margin %	82.22%	75.60%	84.21%	81.64%	88.19%	82.69%	83.63%	89.80%	88.95%	83.63%	89.41%	76.37%	87.02%	86.22%	86.19%	84.86%	89.00%	86.99%	85.03%	86.28%	87.03%	85.92%	82.68%	80.83%	86.63%	83.01%	92.56%	90.33%	89.95%	92.08%	93.38%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%	NaN%
cost of collaborations and royalties	3,602,000		2,923,000	924,000	858,000	168,000	3,925,000	1,401,000	11,363,000	13,883,000	4,836,000	10,034,000	13,437,000	5,094,000	4,609,000	6,770,000	12,170,000	4,029,000	4,572,000	8,499,000
research and development	364,866,000	372,218,000	358,814,000	323,621,000	265,122,000	300,169,000	270,926,000	294,142,000	260,995,000	272,141,000	253,179,000	248,526,000	230,569,000	262,039,000	245,371,000	205,712,000	169,893,000	229,050,000	194,572,000	182,635,000	185,899,000	168,469,000	161,783,000	154,996,000	169,571,000	201,301,000	160,796,000	163,890,000	129,127,000	131,036,000	139,945,000	137,582,000	96,857,000	117,772,000	95,252,000	90,627,000	86,984,000	105,011,000	97,936,000	83,172,000	96,273,000	82,835,000	68,618,000	67,007,000	58,035,000	55,546,000	46,273,000	44,672,000	43,758,000	32,106,000	34,457,000	24,215,000	22,179,000	21,678,000	22,094,000	21,723,000	23,369,000	24,274,000	25,303,000	26,349,000	26,080,000	27,468,000	28,136,000	24,700,000	21,575,000	23,219,000	38,615,000	25,321,000	24,943,000	22,105,000	29,558,000	20,277,000	15,584,000	59,618,000	18,813,000	26,671,000	12,343,000	12,833,000	12,692,000	11,930,000	12,762,000	7,995,000	9,190,000	5,372,000	4,856,250	4,831,000	4,159,000
selling, general and administrative	322,551,000	325,374,000	322,076,000	323,314,000	239,949,000	295,339,000	220,993,000	248,397,000	210,797,000	198,123,000	199,175,000	214,689,000	183,659,000	210,344,000	235,859,000	169,984,000	154,471,000	186,382,000	142,075,000	145,323,000	146,859,000	166,291,000	167,472,000	127,896,000	126,761,000	156,277,000	120,351,000	112,769,000	89,608,000	108,688,000	116,545,000
total operating costs and expenses	898,539,000	965,315,000	881,044,000	789,888,000	576,112,000	698,325,000	577,824,000	611,211,000	537,768,000	556,122,000	536,663,000	548,585,000	469,097,000	523,649,000	522,346,000	416,504,000	359,991,000	453,096,000	369,310,000	366,713,000	363,820,000	357,784,000	351,052,000	302,821,000	309,634,000																																																												7,091,250	7,793,000	7,106,000
income from operations	268,636,000	131,718,000	367,982,000	-16,199,000	18,077,000	-105,159,000	-76,905,000	48,614,000	-43,435,000	-116,404,000	213,867,000	-229,831,000	-149,807,000	-188,614,000	-258,040,000	-191,686,000	-146,732,000	-194,561,000	-181,677,000	-146,160,000	-186,254,000	-194,222,000	-225,199,000	-198,859,000	-210,158,000	-298,073,000	-216,299,000	-236,271,000	-188,788,000	-220,356,000	-254,558,000	-192,354,000	-147,405,000	-147,303,000	-125,800,000	-120,474,000	-106,511,000	-115,433,000	-106,676,000	-92,450,000	-110,028,000	-92,512,000	-78,330,000	-72,944,000	-52,222,000	-45,712,000	-45,199,000	-45,005,000	-269,064,000	-29,592,000	-32,234,000	-21,312,000	-9,804,000	-88,349,000	-18,147,000	-12,067,000	-13,586,000	-12,438,000	-13,118,000	-15,676,000	-12,410,000	-8,728,000	-11,626,000	-11,306,000	-8,069,000	-9,650,000	-22,412,000	-7,980,000	-7,813,000	-3,234,000	-12,831,000	-3,957,000	-2,892,000	-51,338,000	-14,953,000	-23,994,000	-9,991,000	-8,604,000	-11,109,000	-9,797,000	-14,917,000	-10,670,000	-11,204,000	-6,681,000	-5,531,000	-6,426,000	-6,975,000
yoy	1386.07%	-225.26%	-578.49%	-133.32%	-141.62%	-9.66%	-135.96%	-121.15%	-71.01%	-38.28%	-182.88%	19.90%	2.10%	-3.06%	42.03%	31.15%	-21.22%	0.17%	-19.33%	-26.50%	-11.37%	-34.84%	4.11%	-15.83%	11.32%	35.27%	-15.03%	22.83%	28.07%	49.59%	102.35%	59.66%	38.39%	27.61%	17.93%	30.31%	-3.20%	24.78%	36.19%	26.74%	110.69%	102.38%	73.30%	62.08%	-80.59%	54.47%	40.22%	111.17%	2644.43%	-66.51%	77.63%	76.61%	-27.84%	610.32%	38.34%	-23.02%	9.48%	42.51%	12.83%	38.65%	53.80%	-9.55%	-48.13%	41.68%	3.28%	198.39%	74.67%	101.67%	170.16%	-93.70%	-14.19%	-83.51%	-71.05%	496.68%	34.60%	144.91%	-33.02%	-19.36%	-0.85%	46.64%	169.70%	66.04%	60.63%
qoq	103.95%	-64.21%	-2371.63%	-189.61%	-117.19%	36.74%	-258.20%	-211.92%	-62.69%	-154.43%	-193.05%	53.42%	-20.57%	-26.91%	34.62%	30.64%	-24.58%	7.09%	24.30%	-21.53%	-4.10%	-13.76%	13.25%	-5.38%	-29.49%	37.81%	-8.45%	25.15%	-14.33%	-13.44%	32.34%	30.49%	0.07%	17.09%	4.42%	13.11%	-7.73%	8.21%	15.39%	-15.98%	18.93%	18.11%	7.38%	39.68%	14.24%	1.13%	0.43%	-83.27%	809.25%	-8.20%	51.25%	117.38%	-88.90%	386.85%	50.39%	-11.18%	9.23%	-5.18%	-16.32%	26.32%	42.19%	-24.93%	2.83%	40.12%	-16.38%	-56.94%	180.85%	2.14%	141.59%	-74.80%	224.26%	36.83%	-94.37%	243.33%	-37.68%	140.16%	16.12%	-22.55%	13.39%	-34.32%	39.80%	-4.77%	67.70%	20.79%	-13.93%	-7.87%
operating margin %	23.02%	12.01%	29.46%	-2.09%	3.04%	-17.73%	-15.35%	7.37%	-8.79%	-26.47%	28.50%	-72.10%	-46.92%	-56.30%	-97.63%	-85.26%	-68.80%	-75.26%	-96.83%	-66.27%	-104.89%	-118.75%	-178.94%	-191.28%	-211.27%	-415.83%	-308.73%	-528.40%	-567.03%	-1047.67%	-12303.43%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
other income:
interest expense	-69,286,000	-129,337,000	-44,398,000	-40,246,000	-38,646,000	-38,971,000	-34,376,000	-33,258,000	-35,253,000	-31,338,000	-30,893,000	-30,035,000	-28,955,000	-29,913,000	-41,084,000	-42,609,000	-42,362,000	-36,816,000	-40,274,000	-33,416,000	-32,515,000	-28,517,000	-28,731,000	-27,248,000																																													-256,000	-176,000	-208,000	-232,000	-250,000	-272,000	-275,000	-286,000	-296,000	-265,000	-230,000	-238,000	-252,000	-244,000	-248,000	-225,000	-120,000	-175,000	-97,000
interest income	26,598,000	26,630,000	28,681,000	27,486,000	28,673,000	31,019,000	32,146,000	29,182,000	29,645,000	30,406,000	25,425,000	21,075,000	18,655,000				1,012,000	495,000	225,000	409,000	450,000	1,092,000	2,072,000	3,165,000	5,480,000	7,253,000	9,889,000	8,781,000	7,525,000	10,571,000	6,796,000	6,101,000	5,794,000	4,235,000	3,296,000	2,577,000	2,128,000	2,199,000	2,204,000	2,092,000	1,813,000	1,616,000	1,610,000	1,619,000	1,014,000	780,000	753,000	693,000	333,000	285,000	290,000	270,000	224,000	222,000	261,000	271,000	236,000	265,000	322,000	382,000	472,000	602,000	641,000	590,000	843,000	1,036,000	1,458,000	2,048,000	2,679,000	3,486,000	3,547,000	4,702,000	5,814,000	4,311,000	2,578,000	2,690,000	1,824,000	1,555,000	1,538,000	1,260,000	790,000	237,000	258,000	264,000	74,000	185,000	74,000
other income	-4,295,000													11,506,000	-30,233,000	-40,378,000	-51,274,000	-29,420,000	17,490,000	-9,164,000	19,044,000	-21,952,000	-594,000	45,039,000	23,032,000	14,237,000	-2,519,000	-453,000	43,000	-1,295,000	2,925,000	2,208,000	335,000	841,000	-433,000	-523,000	-2,907,000	300,000	401,000	229,000	5,241,000	175,000	-72,000			1,452,000	524,000		-82,000	-29,000	-12,000	-11,000	5,000	164,000	-3,000	-21,000	1,000	-597,000	-16,000	81,000	6,351,000	20,000	43,000	-11,000	484,000	-10,000	-24,000	178,000				82,000					-70,000	-86,000	-109,000	-85,000	22,500	-1,000	49,000	42,000	-9,250		42,000
total other expense	-46,983,000	29,419,000	-129,013,000	-19,159,000	-59,673,000	-88,799,000	-31,758,000	-59,781,000	-20,152,000	-21,283,000	-63,126,000	-44,378,000	-22,555,000	-18,407,000	-147,903,000	-82,987,000
income before income taxes	221,653,000	161,137,000	238,969,000	-35,358,000	-41,596,000	-193,958,000	-108,663,000	-11,167,000	-63,587,000	-137,687,000	150,741,000	-274,209,000	-172,362,000	-207,021,000	-405,943,000	-274,673,000	-239,356,000	-260,302,000	-204,236,000	-188,331,000	-199,275,000	-243,599,000	-252,452,000	-177,903,000	-181,646,000	-276,583,000	-208,929,000	-218,521,000	-181,220,000	-211,080,000	-244,837,000	-163,481,000	-141,276,000							-90,129,000	-102,974,000	-90,721,000	-76,792,000	-71,352,000	-51,208,000	-43,480,000	-43,922,000	-44,389,000	-268,813,000	-29,336,000	-31,956,000	-21,053,000	-9,575,000				-14,303,000	-13,237,000	-13,824,000	-16,285,000	-6,503,000	-9,332,000	-14,861,000	-12,305,000	-8,230,000	-9,760,000	-21,794,000	-7,224,000	-9,336,000	-3,651,000	-11,509,000	-1,034,000	1,722,000	-47,607,000
provision for income taxes	-15,662,000			-30,919,000	-15,883,000	-2,744,250	-2,907,000	-5,722,000	-2,348,000			-1,815,000	-1,739,000			-2,729,000	-985,000	-630,500	-278,000	-1,228,000	-1,016,000			-1,326,000	-575,000			-960,000		-361,000	-445,000	-79,000																																-18,000			-908,000	-665,000			-1,251,000	-205,000	-60,000	-5,185,000
net income	205,991,000	186,419,000	251,084,000	-66,277,000	-57,479,000	-83,763,000	-111,570,000	-16,889,000	-65,935,000	-137,870,000	147,753,000	-276,024,000	-174,101,000	-207,493,000	-405,920,000	-277,402,000	-240,341,000	-258,460,000	-204,514,000	-189,559,000	-200,291,000	-243,540,000	-253,291,000	-179,229,000	-182,221,000	-276,185,000	-208,535,000	-219,481,000	-181,915,000	-211,441,000	-245,282,000	-163,560,000	-141,214,000	-142,227,000	-122,937,000	-118,420,000	-107,290,000	-112,934,000	-104,071,000	-90,129,000	-102,974,000	-90,721,000	-76,792,000	-71,783,000	-50,777,000	-21,389,000	-43,989,000	-44,074,000	-250,943,000	-32,357,000	-29,686,000	-18,169,000	-9,013,000	-62,188,000	-19,502,000	-12,956,000	-14,303,000	-13,237,000	-13,824,000	-16,285,000	-6,930,000	-9,630,000	-14,632,000	-12,323,000	-7,791,000	-9,208,000	-22,702,000	-7,889,000	-9,392,000	-2,858,000	-12,760,000	-1,239,000	1,662,000	-52,792,000	-12,691,000	-21,645,000	-8,438,000	-7,400,000	-9,910,000	-8,860,000	-14,491,000	-10,678,000	-11,145,000	-6,600,000	-5,700,000	-6,416,000	-6,956,000
yoy	-458.38%	-322.56%	-325.05%	292.43%	-12.82%	-39.24%	-175.51%	-93.88%	-62.13%	-33.55%	-136.40%	-0.50%	-27.56%	-19.72%	98.48%	46.34%	20.00%	6.13%	-19.26%	5.76%	9.92%	-11.82%	21.46%	-18.34%	0.17%	30.62%	-14.98%	34.19%	28.82%	48.66%	99.52%	38.12%	31.62%	25.94%	18.13%	31.39%	4.19%	24.48%	35.52%	25.56%	102.80%	324.15%	74.57%	62.87%	-79.77%	-33.90%	48.18%	142.58%	2684.23%	-47.97%	52.22%	40.24%	-36.99%	369.80%	41.07%	-20.44%	106.39%	37.46%	-5.52%	32.15%	-11.05%	4.58%	-35.55%	56.20%	-17.05%	222.18%	77.92%	536.72%	-665.10%	-94.59%	0.54%	-94.28%	-119.70%	613.41%	28.06%	144.30%	-41.77%	-30.70%	-11.08%	34.24%	154.23%	66.43%	60.22%
qoq	10.50%	-25.75%	-478.84%	15.31%	-31.38%	-24.92%	560.61%	-74.39%	-52.18%	-193.31%	-153.53%	58.54%	-16.09%	-48.88%	46.33%	15.42%	-7.01%	26.38%	7.89%	-5.36%	-17.76%	-3.85%	41.32%	-1.64%	-34.02%	32.44%	-4.99%	20.65%	-13.96%	-13.80%	49.96%	15.82%	-0.71%	15.69%	3.81%	10.37%	-5.00%	8.52%	15.47%	-12.47%	13.51%	18.14%	6.98%	41.37%	137.40%	-51.38%	-0.19%	-82.44%	675.54%	9.00%	63.39%	101.59%	-85.51%	218.88%	50.52%	-9.42%	8.05%	-4.25%	-15.11%	134.99%	-28.04%	-34.19%	18.74%	58.17%	-15.39%	-59.44%	187.77%	-16.00%	228.62%	-77.60%	929.86%	-174.55%	-103.15%	315.98%	-41.37%	156.52%	14.03%	-25.33%	11.85%	-38.86%	35.71%	-4.19%	68.86%	15.79%	-11.16%	-7.76%
net income margin %	17.65%	16.99%	20.10%	-8.57%	-9.67%	-14.12%	-22.27%	-2.56%	-13.34%	-31.35%	19.69%	-86.59%	-54.53%	-61.93%	-153.58%	-123.39%	-112.70%	-99.97%	-109.00%	-85.95%	-112.80%	-148.90%	-201.26%	-172.40%	-183.18%	-385.30%	-297.65%	-490.86%	-546.39%	-1005.28%	-11855.10%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%	-Infinity%
net income per common share — basic	1,550	1,410	1,910
net income per common share — diluted	1,510	1,380	1,840
weighted-average common shares — basic	132,893,000	131,004,000	131,447,000
weighted-average common shares — diluted	138,226,000	134,684,000	137,348,000
statements of comprehensive income
other comprehensive loss:
unrealized gains on marketable securities	-3,652,000	-2,000	1,131,000
foreign currency translation losses	-1,234,000
defined benefit pension plans, net of tax	89,000	820,000	53,000	53,000	55,000	-1,589,000	30,000	30,000	33,000	-1,642,000	-10,000	-4,000	-5,000	1,616,000	34,000	34,000	35,000	769,000	58,000	58,000	58,000	-456,000	76,000	72,000	74,000
total other comprehensive loss	-4,797,000				-2,999,000
comprehensive income	201,194,000	188,097,000	259,261,000			-48,961,250	-101,759,000			-72,514,250	152,494,000
loss related to convertible debt		-3,327,000	-39,146,000
other expense		-32,562,250	-74,150,000	-6,399,000	-49,700,000	-80,847,000	-29,528,000	-55,705,000	-14,544,000	-20,351,000	-57,658,000	-35,418,000	-12,255,000																															-27,000				-77,000																					-71,000	-1,546,000	-412,000		-14,000	-169,000	-41,000	-55,000
benefit from income taxes		25,282,000	12,115,000							-1,635,500	-2,988,000			-922,750	23,000																		62,000											-431,000	431,000	22,091,000	-67,000	315,000	17,870,000	-3,021,000	2,270,000	2,884,000	562,000								-427,000	-298,000	229,000		-255,250	552,000			-165,750	793,000
other comprehensive income:
foreign currency translation gains		860,000	6,993,000																	825,000	6,848,000	-416,250	-2,576,000
total other comprehensive income		1,678,000	8,177,000	7,565,000		-9,692,000	9,811,000	-7,649,000	-3,613,000	8,964,000	4,741,000	2,044,000	5,530,000	-871,000	-1,559,000	-4,159,000	-4,806,000	971,000	1,851,000	636,000	6,905,000	-168,750	-3,981,000	-1,153,000
net loss per common share — basic and diluted				-510	-440																																																				-340	-310			-217.5	-230	-350	-290	-180	-220	-550		-230	-70	-310	-30	80	-1,350	-340	-580	-260	-230	-310	-300	-590	-510	-540	-320
weighted-average common shares used to compute basic and diluted net loss per common share				130,628,000	129,676,000	127,651,000		126,733,000	126,138,000	124,906,000		124,659,000	124,111,000	121,689,000	122,166,000	120,896,000	120,393,000	118,451,000	119,141,000	117,772,000	117,080,000	114,986,000	115,986,000	114,911,000	112,748,000	109,264,000	108,701,000	108,576,000	105,400,000	100,590,000	100,783,000	100,519,000	99,979,000	90,554,000	91,828,000	88,098,000	86,027,000	85,596,000	85,716,000	85,545,000	85,277,000	83,992,000	84,633,000	84,353,000	82,074,000	74,278,000	76,408,000	75,835,000	67,786,000	61,551,000	62,416,000	61,661,000	59,173,000	50,286,000	51,542,000	51,280,000	42,410,000	42,654,000				42,123,000	41,991,000	41,870,000	41,633,000	41,708,000	41,520,000	41,399,000	41,077,000	41,197,000	40,908,000	40,736,000	38,657,000				31,890,000	32,122,000	32,010,000	30,028,000	21,949,000	20,913,576,000	20,605,681,000	20,434,896,000		19,507,468,000	6,997,479,000
statements of comprehensive loss
unrealized gain on marketable securities				-343,000	1,030,000	-4,787,000	9,078,000	-727,000	-3,568,000	7,040,000	1,878,000	-2,025,000	4,125,000					-1,666,000	-64,000	-247,000	-1,000																																	68,250	170,000	-25,000	-14,000	95,000	-228,000	-732,000	-574,000	2,000	492,000	107,000	-1,169,000	272,000	1,021,000	-473,000	2,175,000	130,000		336,000	150,000	273,000	-94,000		-12,000	104,000	26,000				33,000
foreign currency translation gain				7,855,000		-3,316,000	703,000	-6,952,000	-78,000	3,566,000	2,873,000	4,073,000	1,410,000	-5,651,000	460,000	-2,459,000	2,376,000	1,868,000	1,857,000
comprehensive loss				-58,712,000	-60,478,000			-24,538,000	-69,548,000			-273,980,000	-168,571,000	-208,364,000	-407,479,000	-281,561,000	-245,147,000	-257,489,000	-202,663,000	-188,923,000	-193,386,000	-249,969,000	-257,272,000	-180,382,000	-177,762,000	-278,332,000	-207,075,000	-222,459,000	-181,555,000	-211,262,000	-244,867,000	-162,514,000	-141,634,000	-142,919,000	-122,719,000	-118,551,000	-107,677,000	-118,597,000	-103,553,000	-109,414,000	-116,354,000	-79,133,000	-102,773,000	-105,406,000	-47,155,000	12,188,000	-50,786,000	-47,121,000	-245,630,000	-39,808,000	-30,648,000	-10,860,000	-3,854,000	-46,634,000	-19,332,000	-12,981,000	-14,317,000	-13,142,000	-14,052,000	-17,017,000	-7,504,000	-9,628,000	-14,169,000	-12,216,000	-8,964,000	-8,940,000	-21,704,000	-8,452,000	-7,108,000	-2,295,000	-15,067,000	-893,000	1,819,000	-53,206,000	-12,757,000	-21,662,000	-8,061,000	-7,249,000	-9,726,000	-8,790,000	-14,601,000	-10,677,000	-11,368,000	-6,829,000	-6,741,500	-6,322,000	-7,062,000
foreign currency translation loss					-4,084,000
net income per common share - basic						-382.5	-870			-607.5	1,180
net income per common share - diluted						-382.5	-870			-607.5	1,150
weighted-average common shares - basic							128,590,000
weighted-average common shares - diluted							128,590,000
net loss per common share - basic and diluted								-130	-520			-2,210	-1,400	-1,905	-3,320	-2,290	-2,000	-1,260	-1,720	-1,610	-1,710	-1,342.5	-2,180	-1,560	-1,620	-1,407.5	-1,920	-2,020	-1,730	-1,370	-2,430	-1,630	-1,410	-982.5	-1,340	-1,340	-1,250	-870	-1,210	-1,050	-1,210	-595	-910	-850	-620	-1,155	-580	-580	-3,700	-232.5	-480	-290				-250												-190
loss on the extinguishment of debt															-76,586,000
weighted-average common shares- basic											125,220,000
weighted-average common shares- diluted											131,337,000
unrealized loss on marketable securities														-2,751,000	-2,053,000	-1,734,000	-7,217,000																																																						-1,808,000					-71,000				-1,000	-39,000	9,000		-31,000
total other income																	-92,624,000	-65,741,000	-22,559,000	-42,171,000	-13,021,000	-49,377,000	-27,253,000	20,956,000	28,512,000	21,490,000	7,370,000	17,750,000	7,568,000	9,276,000	9,721,000	28,873,000	6,129,000	5,076,000	2,863,000	2,054,000	-779,000	2,499,000	2,605,000	2,321,000	7,054,000	1,791,000	1,538,000	1,592,000	1,014,000	2,232,000	1,277,000	616,000	251,000	256,000	278,000	259,000	229,000	15,589,000	-1,355,000	-889,000	-717,000	-799,000	-706,000	-609,000	5,907,000	-604,000	-3,235,000	-999,000	-161,000	-110,000	618,000	756,000	-1,523,000	-417,000	1,322,000	2,923,000	4,614,000	3,731,000	2,262,000	2,349,000	1,553,000	1,204,000	1,199,000	937,000	426,000	-8,000	59,000	81,000	-55,250	10,000	19,000
cost of collaborations																					8,039,000
change in fair value of liability obligation																												9,422,000
benefit for income taxes																						-685,000	-839,000			-315,250	394,000		-695,000
unrealized gain on marketable debt securities																						192,000	-1,481,000	-1,796,000	4,045,000
foreign currency translation																								571,000	340,000	570,250	1,439,000	842,000																																			-29,000		-4,000	-4,000	-23,000	-90,000	109,000	433,000	-499,000	10,000
product revenues																										27,647,000	46,066,000	38,231,000	26,291,000	12,075,000	460,000
net revenue from collaborators																										9,370,250	23,995,000	6,483,000	7,003,000
costs and expenses:
total costs and expenses																										197,356,750	286,360,000	280,985,000	222,082,000	241,389,000	256,627,000																																														12,364,750	16,815,000	17,130,000	15,514,000	16,469,000	12,083,000	12,312,000	8,324,000
gain on litigation settlement																																20,564,000
comprehensive loss:
unrealized gain on marketable securities, net of tax																										193,000	-50,000	462,000	360,000	179,000	415,000	1,046,000		-548,500	218,000			-5,502,000	1,224,000		-8,224,000			-33,623,000	3,622,000	35,091,000	-6,230,000	-3,047,000	5,313,000	-7,451,000	-962,000	7,309,000	5,159,000
defined benefit pension plans																										691,000	71,000
unrealized loss on pension obligation																												-4,282,000
net revenues from collaborators																														8,958,000	1,609,000	29,907,000	21,899,000	37,924,000	17,096,000	15,932,000	18,960,000	17,454,000	13,651,000	8,709,000	7,345,000	7,551,000	6,324,000	8,685,000	18,537,000	24,019,000	10,972,000	7,295,000	8,275,000
reclassification adjustment for realized loss on marketable securities included in net loss																																				345,000	1,549,000
operating expenses:
general and administrative																																84,679,000	72,447,000	67,455,000	47,644,000	45,779,000	38,487,000	27,876,000	22,391,000	17,987,000	21,100,000	17,228,000	16,036,000	14,622,000	12,724,000	14,185,000	9,898,000	11,518,000	8,925,000	8,333,000	6,768,000	5,784,000	6,267,000	10,166,000	12,812,000	11,228,000	10,672,000	8,955,000	8,429,000	10,224,000	7,522,000	8,928,000	10,107,000	11,170,000	13,120,000	10,680,000	8,398,000	7,716,000	7,274,000	6,863,000	7,106,000	5,872,000	5,540,000	8,035,000	5,273,000	4,540,000	4,629,000	3,982,000	4,438,000	3,584,000	3,707,000	4,088,000	3,122,000	2,952,000	2,235,000	2,962,000	2,947,000
total operating expenses																																222,261,000	169,304,000	185,227,000	142,896,000	136,406,000	125,471,000	132,887,000	120,327,000	101,159,000	117,373,000	100,063,000	84,654,000	81,629,000	70,759,000	69,731,000	56,171,000	52,300,000	277,339,000	40,439,000	41,225,000	29,999,000	28,446,000	96,844,000	34,906,000	32,951,000	34,041,000	33,229,000	33,732,000	36,573,000	33,602,000	36,396,000	38,243,000	35,870,000	34,695,000	33,899,000	47,013,000	33,037,000	32,217,000	28,968,000	36,664,000	26,149,000	21,124,000	67,653,000	24,086,000	31,211,000
unrealized loss on marketable securities, net of tax																																	-420,000			-476,000	-1,936,000			-18,331,000		-13,995,500	-25,981,000
reclassification adjustment for realized gain on marketable securities included in net loss																																						-161,000	-706,000	-954,000	-5,156,000					-1,514,000	-567,000
non-cash stock-based compensation expenses included in operating expenses are as follows:
in-process research and development																																																-3,890,000	224,656,000
net revenues from research collaborators																																																		9,080,000	8,991,000	8,687,000	18,642,000	8,495,000	16,759,000	20,884,000	20,455,000	20,791,000	20,614,000	20,897,000	21,192,000	27,668,000	26,617,000	24,564,000	26,626,000	24,249,000	24,601,000	25,057,000	24,404,000	25,734,000	23,833,000	22,192,000	18,232,000	16,315,000	9,133,000	7,217,000
equity in loss of joint venture																																																						-881,000	-1,613,000	-1,139,000	-954,000	-467,000	-1,012,000	-1,072,000	-916,000	-1,226,000	-3,919,000	-1,578,000	-1,488,000	-1,136,000	-816,000	-1,470,000	-3,875,000	-2,181,000	-1,605,000	-1,629,000	-936,000	-139,000
net loss per common share—basic and diluted																																																					-150	-220	-380
net income per common share — basic and diluted																																																											-330	-380
weighted-average common shares used to compute basic and diluted net income per common share																																																											42,379,000	42,345,000	42,040,000
weighted-average common shares — basic and diluted																																																																										39,025,000	37,534,000	37,376,000
foreign currency translation adjustments																																																																									-151,250	-687,000	28,000	54,000	69,000	47,000	158,000	71,000	-71,000	-8,000	-256,000	-198,000	-3,000	94,000	-106,000
non-cash stock-based compensation expense included in these amounts are as follows:
net revenues																																																																													4,987,250	8,211,000	6,021,000	5,717,000	1,041,000	1,413,000	1,108,000	1,643,000
cost and expenses:
total non-cash stock-based compensation																																																																																2,375,000	1,002,000	2,196,000	919,000	480,000
accretion of redeemable convertible preferred stock																																																																																					-678,250		-751,000
net loss attributable to common stockholders																																																																																	-14,491,000	-10,678,000	-11,145,000	-6,600,000	-5,700,000	-6,416,000	-7,707,000
revenue from research collaborators																																																																																					408,000	1,367,000	131,000
net loss per common share																																																																																					-785	-330	-1,100
noncash stock-based compensation expense included in these amounts are as follows:
total stock-based compensation																																																																																					728,750	731,000	-47,000
costs and expenses

Balance Sheets:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30

assets
current assets:
cash and cash equivalents	1,710,779,000	1,657,250,000	1,490,249,000	1,113,685,000	1,019,654,000	966,428,000	1,099,920,000	968,492,000	681,879,000	812,688,000	1,033,024,000	657,800,000	672,245,000	866,394,000	1,073,228,000	575,558,000	534,081,000	819,975,000	1,093,991,000	745,767,000	379,543,000	496,580,000	496,704,000	580,829,000	467,779,000	547,178,000	923,304,000	1,136,289,000	724,959,000	420,146,000	316,608,000	361,457,000	396,149,000	645,361,000	202,045,000	408,671,000	171,079,000	193,617,000	168,481,000	271,076,000	231,278,000	180,895,000	149,218,000	151,262,000	306,580,000	75,179,000	82,721,000	80,727,000	350,589,000	53,169,000	11,840,000	24,975,000	97,804,000	51,405,000	75,838,000	48,274,000	61,739,000	70,228,000	74,336,000	67,110,000	90,590,000	74,599,000	46,881,000	66,182,000	114,947,000	137,468,000	98,087,000	147,870,000	227,268,000	191,792,000	196,737,000	247,536,000	196,281,000	105,157,000	200,547,000	84,464,000	66,662,000	127,955,000	35,516,000	35,645,000	56,804,000	15,757,000	7,178,000	9,165,000	12,215,000	20,272,000	14,544,000	31,891,000
marketable debt securities	1,298,444,000	1,251,234,000	1,234,375,000	1,743,900,000	1,605,368,000	1,719,920,000	1,671,993,000	1,646,268,000	1,678,147,000	1,615,516,000	1,362,843,000	1,372,451,000	1,372,574,000	1,297,890,000	1,169,050,000	1,504,154,000	1,673,485,000	1,548,617,000	1,161,324,000	1,101,782,000	1,273,027,000	1,333,182,000	1,279,955,000	1,258,425,000	836,346,000	975,017,000	797,754,000	790,542,000	519,578,000	662,803,000	905,222,000	1,074,165,000
accounts receivable	883,957,000	777,567,000	964,768,000	567,112,000	418,035,000	405,308,000	353,852,000	309,481,000	321,377,000	327,787,000	325,445,000	220,635,000	219,434,000	237,963,000	184,513,000	142,271,000	156,533,000	198,571,000	141,064,000	146,587,000	110,626,000	102,413,000	79,118,000	69,115,000	75,572,000	43,011,000	48,109,000	30,739,000	33,801,000	18,760,000	3,362,000
inventory	84,025,000	82,719,000	75,383,000	71,688,000	65,581,000	78,509,000	75,987,000	83,981,000	93,988,000	89,146,000	95,771,000	100,453,000	131,879,000	128,962,000	115,489,000	88,976,000	78,516,000	86,363,000	97,899,000	84,358,000	73,940,000	75,202,000	66,942,000	77,418,000	68,300,000	56,348,000	54,562,000	40,587,000	32,001,000	24,068,000	11,081,000
prepaid expenses and other current assets	242,103,000	281,892,000	188,036,000	147,314,000	152,420,000	116,964,000	145,350,000	154,745,000	201,960,000	126,382,000	157,958,000	145,452,000	119,030,000	132,916,000	125,516,000	129,778,000	115,065,000	88,078,000	108,534,000	94,136,000	75,980,000	62,767,000	74,766,000	88,349,000	98,698,000	80,343,000	73,536,000	65,616,000	81,674,000	73,713,000	90,843,000	51,932,000	66,665,000	40,120,000	30,430,000	22,033,000	18,127,000	21,744,000	19,282,000	22,152,000	27,626,000	16,559,000	17,453,000	15,117,000	13,206,000	9,739,000	10,699,000	10,270,000	8,409,000	3,910,000	4,776,000	4,205,000	3,542,000	2,540,000	5,679,000	6,933,000	7,252,000	4,158,000	4,909,000	5,077,000	4,919,000	6,889,000	6,432,000	6,021,000	5,109,000	4,151,000	5,173,000	5,327,000	5,454,000	4,674,000	4,523,000	4,182,000	1,922,000	2,926,000	4,125,000	1,575,000	1,057,000	1,695,000	1,706,000	2,199,000	1,729,000	1,657,000	1,301,000	1,238,000	988,000	966,000	1,345,000	1,413,000
total current assets	4,219,308,000	4,050,662,000	3,952,811,000	3,643,699,000	3,268,258,000	3,295,285,000	3,355,424,000	3,172,856,000	2,988,607,000	2,982,697,000	2,985,452,000	2,524,047,000	2,541,018,000	2,692,247,000	2,690,847,000	2,471,638,000	2,589,677,000	2,808,576,000	2,675,362,000	2,725,163,000	2,470,083,000	2,614,777,000	2,554,702,000	2,160,446,000	1,584,773,000	1,715,864,000	1,897,265,000	2,063,773,000	1,392,013,000	1,200,696,000	1,342,120,000	1,502,559,000	1,685,297,000	1,764,740,000	993,368,000	960,709,000	597,188,000	671,877,000	747,564,000	888,068,000	1,050,074,000	1,105,388,000	1,041,793,000	1,029,150,000	1,090,186,000	746,367,000	643,017,000	665,121,000	674,063,000	254,028,000	199,164,000	214,359,000	240,111,000	125,456,000	235,933,000	240,342,000	208,539,000	152,028,000	179,957,000	224,334,000	250,709,000	254,139,000	244,623,000	273,510,000	273,309,000	293,534,000	228,165,000	278,422,000	419,339,000	442,249,000	451,779,000	550,631,000	455,475,000	463,559,000	477,632,000	201,958,000	209,916,000	222,784,000	126,827,000	129,057,000	137,120,000	82,414,000	26,697,000	33,840,000	41,442,000		47,198,000	50,511,000
property, plant and equipment	518,257,000	513,147,000	501,754,000	499,791,000	498,684,000	502,784,000	506,997,000	517,159,000	523,460,000	526,057,000	525,591,000	527,474,000	523,032,000	523,494,000	514,821,000	508,201,000	504,389,000	501,958,000	484,941,000	470,700,000	464,572,000	465,029,000	444,690,000	439,126,000	429,814,000	425,179,000	396,456,000	371,769,000	341,712,000	320,658,000	272,652,000	227,839,000	201,979,000	181,900,000	161,899,000	147,533,000	129,962,000	114,572,000
operating lease right-of-use assets	189,299,000	194,916,000	191,390,000	192,401,000	197,233,000	191,148,000	196,408,000	198,303,000	195,468,000	199,732,000	203,485,000	208,801,000	215,049,000	215,136,000	218,802,000	223,921,000	228,769,000	231,675,000	235,853,000	238,089,000	237,213,000	241,485,000	245,234,000	229,674,000	221,280,000	221,197,000	223,444,000	226,357,000	226,412,000
deferred tax assets	116,960,000	125,975,000	98,558,000	104,363,000	107,224,000	116,863,000																																					9,406,000	19,654,000	33,667,000	31,667,000																	1,943,000	1,937,000	1,937,000	1,937,000	5,312,000	5,606,000	5,606,000	5,382,000
restricted investments	22,170,000	22,170,000	51,314,000	68,593,000	68,592,000	68,593,000	68,592,000	49,391,000	49,390,000	49,391,000	49,390,000	49,388,000	49,388,000	49,390,000	49,389,000	49,390,000	40,889,000	40,891,000	40,890,000	40,890,000	40,725,000	40,725,000	24,725,000	24,725,000	24,725,000	14,825,000	14,825,000	44,825,000	44,825,000	44,825,000	44,825,000	44,825,000	30,000,000	30,000,000	150,000,000	150,000,000	150,000,000	150,000,000	150,000,000	150,000,000
other assets	63,553,000	59,461,000	55,835,000	57,172,000	73,820,000	65,310,000	77,618,000	71,925,000	67,461,000	72,003,000	75,155,000	92,686,000	63,453,000	66,092,000	61,396,000	77,267,000	69,821,000	60,204,000	35,267,000	34,587,000	42,676,000	45,045,000	37,932,000	20,396,000	19,032,000	18,069,000	9,632,000	9,687,000	9,037,000	8,623,000	16,057,000	14,166,000	5,215,000	4,171,000	1,471,000	1,471,000	1,471,000	1,562,000	1,561,000	1,471,000	1,471,000	1,471,000												101,000																	89,000	116,000	145,000	173,000	201,000	685,000	749,000	803,000	351,000	416,000	508,000	550,000	428,000	457,000	485,000	514,000
total assets	5,129,547,000	4,966,331,000	4,851,662,000	4,566,019,000	4,213,811,000	4,239,983,000	4,205,039,000	4,009,634,000	3,824,386,000	3,829,880,000	3,839,073,000	3,402,396,000	3,391,940,000	3,546,359,000	3,535,255,000	3,330,417,000	3,433,545,000	3,643,304,000	3,472,313,000	3,509,429,000	3,255,269,000	3,407,061,000	3,307,283,000	3,374,367,000	2,279,624,000	2,395,134,000	2,541,622,000	2,716,411,000	2,013,999,000	1,574,802,000	1,675,654,000	1,789,389,000	1,923,139,000	1,994,730,000	1,358,281,000	1,434,283,000	1,133,926,000	1,262,810,000	1,312,910,000	1,382,162,000	1,316,949,000	1,386,510,000	1,436,144,000	1,530,771,000	1,628,790,000	1,079,595,000	986,357,000	1,032,659,000	1,080,297,000	420,530,000	447,503,000	462,558,000	471,578,000	287,520,000	322,352,000	318,477,000	340,295,000	281,917,000	310,223,000	340,828,000	369,052,000	393,265,000	412,606,000	440,180,000	463,406,000	481,385,000	495,668,000	518,653,000	554,529,000	554,676,000	580,181,000	580,046,000	486,256,000	493,791,000	505,091,000	219,658,000	227,340,000	240,006,000	144,527,000	147,114,000	153,687,000	98,348,000	43,248,000	50,862,000	59,067,000		62,545,000	68,473,000
liabilities and stockholders' equity
current liabilities:
accounts payable	126,628,000	115,721,000	117,591,000	102,393,000	97,399,000	88,415,000	70,805,000	73,980,000	78,148,000	55,519,000	73,840,000	59,746,000	62,237,000	98,094,000	40,572,000	52,418,000	54,916,000	73,426,000	40,048,000	53,079,000	45,381,000	51,966,000	27,872,000	26,125,000	40,484,000	49,884,000	39,392,000	71,215,000	22,671,000	59,708,000	21,772,000	11,988,000	13,206,000	28,355,000	9,239,000	23,170,000	25,371,000	54,465,000	23,137,000	12,824,000	17,442,000	16,787,000	14,272,000	15,715,000	15,486,000	15,111,000	5,201,000	6,168,000	5,037,000	5,896,000	2,728,000	4,534,000	3,105,000	4,420,000	5,093,000	5,519,000	4,339,000	5,800,000	5,486,000	7,949,000	5,800,000	9,312,000	6,561,000	10,398,000	6,988,000	12,489,000	8,426,000	6,463,000	8,729,000	2,588,000	3,342,000	6,240,000	9,084,000	3,826,000	7,057,000	5,669,000	3,007,000	4,085,000	2,456,000	3,698,000	3,928,000	1,975,000	1,985,000	1,612,000	1,653,000	910,000	1,450,000	1,810,000
accrued expenses	946,485,000	1,080,197,000	1,153,648,000	918,966,000	704,165,000	887,472,000	946,168,000	808,643,000	698,865,000	713,013,000	713,094,000	598,530,000	508,599,000	545,460,000	510,579,000	421,243,000	355,936,000	395,174,000	388,576,000	341,187,000	280,527,000	355,909,000	295,260,000	211,186,000	183,221,000	197,201,000	177,948,000	138,800,000	106,873,000	112,719,000	93,564,000	89,867,000	63,824,000	72,203,000	51,260,000	43,820,000	31,842,000	42,118,000	36,211,000	37,551,000	30,805,000	28,798,000	18,444,000	17,758,000	14,427,000	23,680,000	19,799,000	15,783,000	16,600,000	14,160,000	15,386,000	8,488,000	9,086,000	11,558,000	14,914,000	14,228,000	13,006,000	12,340,000	12,230,000	11,380,000	12,050,000	11,116,000	10,880,000	7,425,000	8,754,000	9,833,000	8,381,000	9,908,000	10,389,000	9,328,000	9,859,000	9,497,000	9,666,000	11,724,000	11,746,000	9,980,000	7,297,000	4,479,000	5,104,000	4,583,000	3,669,000	3,899,000
operating lease liabilities	45,661,000	45,518,000	44,755,000	46,097,000	46,011,000	41,886,000
deferred revenue	3,213,000	4,845,000	2,541,000	15,080,000	28,160,000	55,481,000	71,030,000	69,009,000	76,850,000	102,753,000	77,140,000	54,639,000	35,794,000	42,105,000	144,208,000	114,292,000	131,838,000	149,483,000	115,044,000	98,144,000	116,340,000	127,207,000	114,601,000	107,587,000	86,043,000	77,821,000	107,359,000	89,242,000	2,642,000	3,496,000	3,444,000	9,161,000	35,855,000	41,705,000	38,532,000	39,794,000	36,755,000	33,540,000	21,087,000	18,885,000	16,944,000	15,352,000	13,973,000	12,460,000	14,099,000	23,871,000	30,270,000	27,002,000	29,121,000	32,696,000	33,558,000	33,560,000	33,548,000	31,417,000	31,156,000	35,345,000	48,410,000	62,366,000	75,727,000	80,721,000	81,010,000	81,134,000	81,270,000	83,100,000	81,893,000	81,929,000	82,420,000	82,570,000	82,539,000	79,864,000	80,048,000	80,806,000	58,822,000	59,249,000	61,652,000	7,840,000	9,899,000	11,144,000	10,924,000	9,599,000	10,387,000	10,734,000	1,266,000	1,390,000	1,519,000	1,000,000	1,071,000	1,451,000
liabilities related to the sale of future royalties and development funding	227,488,000	220,068,000
total current liabilities	1,349,475,000	1,466,349,000	1,555,477,000	1,300,847,000	1,075,623,000	1,186,272,000	1,220,663,000	1,055,251,000	941,709,000	967,786,000	949,785,000	788,639,000	673,391,000	767,915,000	772,791,000	657,685,000	605,963,000	695,710,000	610,656,000	554,648,000	494,825,000	585,270,000	480,241,000	384,302,000	338,791,000	352,594,000	352,864,000	328,604,000	149,163,000	179,494,000	121,503,000	113,659,000	115,383,000	144,251,000	101,045,000	108,726,000	95,786,000	131,699,000	81,761,000	70,575,000	66,369,000	62,099,000	57,112,000	66,598,000	80,693,000	95,334,000	56,849,000	53,745,000	83,831,000	53,864,000	54,895,000	53,066,000	49,750,000	48,345,000	54,758,000	57,064,000	66,638,000	80,990,000	93,927,000	100,534,000	99,344,000	102,046,000	99,433,000	102,033,000	98,571,000	110,733,000	101,121,000	102,331,000	104,251,000	99,452,000	102,024,000	105,727,000	84,910,000	82,091,000	87,456,000	27,106,000	23,498,000	22,925,000	21,530,000	20,601,000	19,990,000	18,484,000	8,002,000	9,021,000	6,138,000		6,640,000	8,704,000
operating lease liabilities, net of current portion	218,025,000	225,087,000	223,421,000	224,445,000	230,061,000	229,541,000
convertible debt	1,009,372,000	1,007,784,000	1,040,276,000	1,026,522,000	1,025,566,000	1,024,621,000	1,023,654,000	1,022,688,000	1,021,732,000	1,020,776,000	1,019,809,000	1,018,843,000	1,017,887,000	1,016,942,000	1,015,975,000
liabilities related to the sale of future royalties and development funding, net of current portion	1,469,684,000	1,470,341,000
other liabilities	7,611,000	7,594,000	9,769,000	10,932,000	5,871,000	398,108,000	357,477,000	350,428,000	319,990,000	308,438,000	280,734,000	257,054,000	224,046,000	212,580,000	183,001,000	157,301,000	120,828,000	98,963,000	76,450,000	71,633,000	60,461,000	37,908,000	16,341,000	18,855,000	9,198,000	9,330,000	9,036,000	9,514,000	5,072,000	4,965,000	4,335,000	4,186,000	4,458,000	4,347,000	2,842,000	2,815,000	3,184,000	3,067,000	1,991,000	1,777,000	1,373,000	1,301,000					500,000	1,000,000	1,000,000
total liabilities	4,054,167,000	4,177,155,000	4,617,768,000	4,315,428,000	4,098,376,000	4,172,895,000	4,172,685,000	4,012,701,000	4,043,658,000	4,050,524,000	4,004,939,000	3,810,527,000	3,651,180,000	3,704,582,000	3,602,893,000	3,154,377,000	3,032,379,000	3,055,101,000	2,716,420,000	2,656,067,000	2,329,079,000	2,390,814,000	2,092,260,000	1,974,641,000	929,895,000	956,442,000	934,535,000	959,216,000	467,013,000	272,837,000	197,535,000	168,587,000	168,334,000	228,299,000	299,446,000	311,317,000	303,025,000	342,589,000	297,942,000	283,680,000	127,898,000	121,796,000	114,540,000	122,167,000	132,280,000	143,328,000	81,879,000	90,390,000	125,324,000	150,183,000	149,921,000	154,383,000	160,022,000	153,467,000	145,192,000	130,190,000	142,917,000	163,920,000	182,350,000	204,277,000	223,485,000	235,032,000	251,963,000	274,702,000	291,576,000	303,420,000	313,647,000	334,171,000	355,785,000	352,551,000	375,624,000	380,877,000	283,444,000	294,623,000	312,156,000	40,388,000	37,313,000	38,832,000	39,750,000	37,037,000	35,771,000	36,569,000	20,177,000	21,474,000	19,238,000		17,564,000	17,798,000
commitments and contingencies
stockholders' equity:
preferred stock, 0.01 par value per share...
common stock, 0.01 par value per share...	1,334,000	1,324,000	1,318,000	1,310,000	1,303,000	1,293,000	1,289,000	1,281,000	1,265,000	1,259,000	1,255,000	1,250,000	1,243,000	1,240,000	1,230,000	1,210,000	1,207,000	1,202,000	1,195,000	1,186,000	1,173,000	1,164,000	1,161,000	1,156,000	1,131,000	1,122,000	1,113,000	1,110,000	1,064,000	1,011,000	1,009,000	1,005,000	1,005,000	997,000	924,000	917,000	861,000	859,000	858,000	856,000	855,000	851,000				772,000	767,000	763,000		637,000				525,000				427,000				423,000
additional paid-in capital	7,595,473,000	7,510,473,000	7,414,771,000	7,690,737,000	7,496,876,000	7,388,061,000	7,259,876,000	7,122,704,000	6,881,977,000	6,811,063,000	6,736,939,000	6,647,173,000	6,522,091,000	6,454,540,000	6,336,771,000	6,172,990,000	6,116,558,000	6,058,453,000	5,968,661,000	5,863,476,000	5,747,394,000	5,644,074,000	5,592,884,000	5,520,320,000	5,289,966,000	5,201,176,000	5,091,248,000	5,034,284,000	4,601,662,000	4,175,139,000	4,140,033,000	4,037,853,000	4,009,342,000	3,947,552,000	3,097,110,000	3,038,529,000	2,627,969,000	2,609,614,000	2,585,765,000	2,565,728,000	2,546,884,000	2,506,197,000	2,483,958,000	2,468,187,000	2,450,690,000	1,843,362,000	1,823,766,000	1,810,775,000	1,776,366,000	846,228,000	833,660,000	813,613,000	806,137,000	624,876,000	621,350,000	613,149,000	609,260,000	518,731,000	514,290,000	509,826,000	504,793,000	500,443,000	495,350,000	490,558,000	482,743,000	476,663,000	471,755,000	465,277,000	457,838,000	452,767,000	448,092,000	440,410,000	428,990,000	424,453,000	420,039,000	353,221,000	351,252,000	340,779,000	236,416,000	235,264,000	234,057,000	170,033,000	117,176,000	112,902,000	112,158,000	112,216,000	106,403,000	107,526,000
accumulated other comprehensive loss	-24,894,000	-20,097,000	-21,775,000	-29,952,000	-37,517,000	-34,518,000	-24,826,000	-34,637,000	-26,988,000	-23,375,000	-32,339,000	-37,080,000	-39,124,000	-44,654,000	-43,783,000	-42,224,000	-38,065,000	-33,259,000	-34,230,000	-36,081,000	-36,717,000	-43,622,000	-37,193,000	-33,212,000	-32,059,000	-36,518,000	-34,371,000	-35,831,000	-32,853,000	-33,213,000	-33,392,000	-33,807,000	-34,853,000	-34,433,000	-33,741,000	-33,959,000	-33,828,000																			-62,000	-37,000																								-71,000
accumulated deficit	-6,496,533,000	-6,702,524,000	-7,160,420,000	-7,411,504,000	-7,345,227,000	-7,287,748,000	-7,203,985,000	-7,092,415,000	-7,075,526,000	-7,009,591,000	-6,871,721,000	-7,019,474,000	-6,743,450,000	-6,569,349,000	-6,361,856,000	-5,955,936,000	-5,678,534,000	-5,438,193,000	-5,179,733,000	-4,975,219,000	-4,785,660,000	-4,585,369,000	-4,341,829,000	-4,088,538,000	-3,909,309,000	-3,727,088,000	-3,450,903,000	-3,242,368,000	-3,022,887,000	-2,840,972,000	-2,629,531,000	-2,384,249,000	-2,220,689,000	-2,147,685,000	-2,005,458,000	-1,882,521,000	-1,764,101,000	-1,656,811,000	-1,543,877,000	-1,439,806,000	-1,349,677,000	-1,246,703,000	-1,155,982,000	-1,079,190,000	-1,007,407,000	-956,630,000	-935,241,000	-891,252,000	-847,178,000	-596,235,000	-563,878,000	-534,192,000	-516,023,000	-507,010,000	-444,822,000	-425,320,000	-412,364,000	-400,996,000	-386,693,000	-373,456,000	-359,632,000	-343,347,000	-336,417,000	-326,787,000	-312,155,000	-299,832,000	-292,041,000	-282,833,000	-260,131,000	-252,242,000	-242,850,000	-239,992,000	-227,232,000	-225,993,000	-227,655,000	-174,863,000	-162,171,000	-140,527,000	-132,089,000	-124,689,000	-114,779,000	-105,919,000	-91,428,000	-80,750,000	-69,604,000	-63,005,000	-57,305,000	-50,889,000
total stockholders' equity	1,075,380,000	789,176,000	233,894,000	250,591,000	115,435,000
total liabilities and stockholders' equity	5,129,547,000	4,966,331,000	4,851,662,000	4,566,019,000	4,213,811,000
marketable equity securities					7,200,000	8,156,000	8,322,000	9,889,000	11,256,000	11,178,000	10,411,000	27,256,000	25,856,000	28,122,000	23,051,000	30,901,000	31,997,000	66,972,000	72,550,000	52,533,000	56,967,000	44,633,000	57,217,000	86,310,000	38,078,000	13,967,000				1,206,000	15,004,000	12,044,000
development derivative liability			121,251,000	120,788,000	118,095,000
development derivative liability, net of current portion			439,659,000	407,535,000	422,434,000
liability related to the sale of future royalties			115,691,000	97,523,000	81,793,000	113,018,000	90,516,000	61,963,000	46,174,000	54,991,000	44,195,000	33,650,000	23,706,000	40,289,000	35,851,000	28,496,000	21,983,000	37,079,000	26,376,000	22,876,000	13,660,000	13,316,000	10,316,000	5,957,000
liability related to the sale of future royalties, net of current portion			1,349,166,000	1,345,147,000	1,338,821,000	1,334,353,000	1,333,849,000	1,342,580,000	1,336,892,000	1,322,248,000	1,310,814,000	1,298,446,000	1,285,200,000	1,252,015,000	1,231,873,000	1,214,311,000	1,193,822,000	1,151,024,000	1,132,362,000	1,105,685,000	1,086,065,000	1,058,225,000	1,032,708,000	1,008,336,000
liabilities and stockholders’ equity
deferred revenue, net of current portion							1,012,000	2,402,000	185,506,000	188,175,000	196,086,000	194,129,000	191,257,000	193,791,000	132,930,000	175,341,000	157,668,000	152,360,000	177,123,000	202,391,000	208,123,000	225,094,000	265,708,000	281,530,000	306,124,000	318,383,000	296,179,000	313,887,000	478,000	458,000	1,623,000	4,522,000	7,676,000	43,075,000	38,356,000	42,079,000	46,049,000	49,392,000	55,894,000	54,810,000	53,952,000	52,965,000	52,117,000	50,256,000	46,566,000	42,983,000	20,028,000	32,548,000	37,674,000	93,394,000	91,779,000	97,636,000	105,980,000	100,874,000	85,029,000	68,108,000	72,374,000	78,487,000	84,810,000	100,122,000	120,200,000	129,974,000	149,666,000	169,958,000	190,248,000	189,884,000	209,677,000	229,669,000	248,959,000	250,121,000	269,441,000	268,868,000	191,440,000	204,067,000	217,051,000	5,105,000	5,655,000	6,786,000	8,473,000	6,685,000	8,070,000	10,099,000
stockholders’ equity
total stockholders’ equity						67,088,000	32,354,000									176,040,000	401,166,000	588,203,000	755,893,000	853,362,000	926,190,000	1,016,247,000	1,215,023,000	1,399,726,000	1,349,729,000	1,438,692,000	1,607,087,000	1,757,195,000	1,546,986,000	1,301,965,000	1,478,119,000	1,620,802,000	1,754,805,000	1,766,431,000	1,058,835,000	1,122,966,000	830,901,000	920,221,000	1,014,968,000	1,098,482,000	1,189,051,000	1,264,714,000	1,321,604,000	1,408,604,000	1,496,510,000	936,267,000	904,478,000	942,269,000	954,973,000	270,347,000	297,582,000	308,175,000	311,556,000	134,053,000	177,160,000	188,287,000	197,378,000	117,997,000	127,873,000	136,551,000	145,567,000	158,233,000	160,643,000	165,478,000	171,830,000	177,965,000	182,021,000	184,482,000	198,744,000	202,125,000	204,557,000	199,169,000	202,812,000	199,168,000	192,935,000	179,270,000	190,027,000	201,174,000	104,777,000	110,077,000	117,916,000	61,779,000	23,071,000	29,388,000	39,829,000		44,981,000	50,675,000
total liabilities and stockholders’ equity						4,239,983,000	4,205,039,000									3,330,417,000	3,433,545,000	3,643,304,000	3,472,313,000	3,509,429,000	3,255,269,000	3,407,061,000	3,307,283,000	3,374,367,000	2,279,624,000	2,395,134,000	2,541,622,000	2,716,411,000	2,013,999,000	1,574,802,000	1,675,654,000	1,789,389,000	1,923,139,000	1,994,730,000	1,358,281,000	1,434,283,000	1,133,926,000	1,262,810,000	1,312,910,000	1,382,162,000	1,316,949,000	1,386,510,000	1,436,144,000	1,530,771,000	1,628,790,000	1,079,595,000	986,357,000	1,032,659,000	1,080,297,000	420,530,000	447,503,000	462,558,000	471,578,000	287,520,000	322,352,000	318,477,000	340,295,000	281,917,000	310,223,000	340,828,000	369,052,000	393,265,000	412,606,000	440,180,000	463,406,000	481,385,000	495,668,000	518,653,000	554,529,000	554,676,000	580,181,000	580,046,000	486,256,000	493,791,000	505,091,000	219,658,000	227,340,000	240,006,000	144,527,000	147,114,000	153,687,000	98,348,000	43,248,000	50,862,000	59,067,000
operating lease liability							42,144,000	41,656,000	41,672,000	41,510,000	41,516,000	42,074,000	43,055,000	41,967,000	41,581,000	41,236,000	41,290,000	40,548,000	40,612,000	39,362,000	38,917,000	36,872,000	32,192,000	33,447,000	29,043,000	27,688,000	28,165,000	29,347,000	16,977,000
operating lease liability, net of current portion							236,030,000	239,352,000	237,829,000	243,101,000	247,711,000	253,416,000	259,399,000	261,339,000	266,323,000	272,016,000	277,388,000	281,347,000	286,030,000	288,559,000	288,015,000	293,039,000	297,262,000	281,618,000	275,782,000	276,135,000	276,456,000	277,211,000	282,300,000
liabilities and stockholders’ deficit
stockholders’ deficit:
total stockholders’ deficit								-3,067,000	-219,272,000	-220,644,000	-165,866,000	-408,131,000	-259,240,000
total liabilities and stockholders’ deficit								4,009,634,000	3,824,386,000	3,829,880,000	3,839,073,000	3,402,396,000	3,391,940,000
liabilities and stockholders’ (deficit) equity
long-term debt																677,723,000	676,710,000	675,697,000	433,799,000	433,151,000	191,590,000	191,278,000						30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	30,000,000	150,000,000	150,000,000	150,000,000	150,000,000	150,000,000	150,000,000
stockholders’ (deficit) equity:
total stockholders’ (deficit) equity														-158,223,000	-67,638,000
total liabilities and stockholders’ (deficit) equity														3,546,359,000	3,535,255,000
stockholders’ equity:
receivable related to the sale of future royalties																				500,000,000	500,000,000	500,000,000	500,000,000	500,000,000
deferred rent																														3,571,000	2,723,000	2,643,000	2,498,000	1,988,000	2,014,000	1,942,000	1,818,000	1,576,000	1,326,000	1,315,000	1,178,000	1,162,000	1,017,000	1,011,000	1,010,000	1,005,000	723,000	711,000	869,000	1,112,000	1,200,000	1,252,000	988,000	950,000	840,000	608,000	608,000	484,000	484,000	484,000	484,000	484,000	485,000	838,000	838,000	838,000	837,000	1,561,000	1,561,000	1,561,000	1,561,000	5,074,000	4,853,000	5,200,000	3,120,000	3,271,000	3,095,000	3,202,000	3,310,000	3,417,000	2,391,000	2,467,000	2,574,000	2,682,000	2,789,000	2,896,000
deferred rent, net of current portion																														57,920,000	40,074,000	16,220,000	10,817,000	6,626,000	7,203,000	7,697,000	8,006,000	8,431,000	8,296,000	6,518,000	6,204,000	5,431,000	5,311,000	5,313,000	5,021,000	5,011,000	4,502,000	3,097,000	2,819,000	2,925,000	3,247,000	3,681,000	4,292,000	4,248,000	4,884,000	4,328,000	3,202,000	3,727,000	2,884,000	2,879,000	2,874,000	2,869,000	2,864,000	2,543,000	2,576,000	2,609,000	2,642,000	1,951,000	2,342,000	2,732,000	3,122,000
billed and unbilled collaboration receivables																																2,961,000	50,768,000	34,002,000	14,644,000	15,405,000	19,457,000	23,334,000	15,146,000	9,514,000	8,814,000	8,298,000	8,130,000	9,403,000	10,107,000	39,937,000	384,000	89,000	164,000	4,248,000	609,000	460,000	558,000	104,000	1,918,000	4,385,000	2,192,000	1,468,000
marketable securities																																	1,171,715,000	1,045,257,000	746,249,000	514,600,000	385,843,000	424,185,000	531,041,000	571,994,000	748,422,000	848,217,000	828,427,000	788,740,000	660,403,000	526,929,000	507,927,000	524,585,000	314,901,000	192,701,000	181,939,000	184,719,000	138,207,000	71,407,000	152,498,000	180,750,000	137,356,000	76,174,000	98,685,000	150,839,000	154,050,000	158,532,000	184,486,000	193,012,000	146,811,000	143,934,000	119,883,000	119,368,000	180,786,000	238,596,000	223,379,000	290,787,000	247,592,000	350,445,000	267,831,000	110,304,000	137,804,000	89,305,000	84,758,000	87,622,000	75,471,000	64,245,000	17,631,000	22,477,000	26,075,000		30,393,000	14,207,000
investment in equity securities of regulus therapeutics inc.																																					2,682,000	8,997,000	13,614,000	13,332,000	33,934,000	51,419,000	38,565,000	64,628,000	99,890,000		41,286,000	49,450,000	55,478,000	45,452,000	57,999,000	60,336,000	47,666,000
accumulated other comprehensive income																																						-33,441,000	-27,778,000	-28,296,000	-9,011,000	4,369,000	-7,219,000	18,762,000	52,385,000	48,763,000	15,186,000	21,983,000	25,030,000	19,717,000	27,168,000	28,130,000	20,821,000	15,662,000				-165,000	-151,000	-246,000	-18,000	714,000	1,288,000	1,286,000	823,000	716,000	1,889,000	1,621,000	623,000	1,186,000	-1,099,000	-1,660,000	646,000	300,000	145,000	558,000	624,000	640,000				-142,000	-32,000	-32,000	191,000	420,000	41,000	-37,000
property and equipment																																							74,219,000	55,394,000	36,814,000	27,812,000	26,316,000	25,169,000	21,166,000	21,740,000	18,806,000	16,953,000	15,731,000	16,448,000	16,974,000	18,045,000	18,983,000	19,799,000	18,792,000	14,206,000	13,703,000	14,643,000	15,309,000	16,252,000	17,021,000	18,289,000	18,399,000	18,554,000	18,304,000	18,324,000	18,152,000	18,483,000	19,321,000	19,194,000	19,577,000	18,853,000	15,875,000	13,810,000	10,434,000	12,965,000	12,527,000	12,173,000	12,856,000	13,044,000	11,359,000	10,580,000	10,760,000	11,084,000	11,540,000	11,694,000	8,969,000	11,436,000
deferred tax liabilities																																											9,406,000	19,654,000	33,667,000	31,667,000
preferred stock, 0.01 par value...
common stock, 0.01 par value...																																											847,000	845,000	842,000				755,000		632,000	624,000	621,000		524,000	520,000	519,000		427,000	427,000	424,000		422,000	421,000	419,000	418,000	418,000	417,000	414,000	414,000	414,000	411,000	408,000	408,000	406,000	376,000	375,000	371,000	322,000	321,000	320,000	267,000	212,000	209,000	209,000		201,000	200,000
accrued intraperiod tax allocation																																													2,004,000		856,000	4,081,000	6,825,000		2,023,000	5,232,000	3,023,000
investment in equity securities of regulus therapeutics inc																																														94,583,000								38,748,000
liability for stock issuance																																																	25,379,000
other long-term liabilities																																																							521,000	690,000	703,000	716,000	729,000	742,000	1,067,000	143,000		168,000	181,000	194,000	207,000	220,000	233,000	246,000	318,000	270,000	286,000	302,000	583,000
investment in joint venture																																																										564,000	1,421,000	1,801,000	2,709,000	3,616,000	20,000	1,183,000	5,032,000	6,435,000	7,867,000	8,901	9,713,000	1,583,000	4,699,000	6,412,000	7,684,000	9,129,000	9,901,000
intangible assets																																																							145,000	188,000	231,000	275,000	318,000	361,000	405,000	448,000	491,000	535,000	578,000	622,000	665,000	708,000	751,000	795,000	838,000	882,000	925,000	968,000	1,610,000	1,737,000	1,835,000	1,933,000				2,491,000				3,405,000	3,523,000	3,642,000
accumulated other comprehensive gain																																																							108,000																								263,000	113,000
income taxes receivable																																																														10,669,000
collaboration receivables																																																											2,027,000	1,308,000	1,150,000	3,450,000	4,881,000	6,358,000	4,505,000	6,044,000	5,022,000	5,857,000	5,831,000	4,188,000	24,140,000	5,126,000	9,680,000	5,031,000	5,129,000	5,615,000	4,393,000	3,829,000	4,847,000	3,591,000	3,116,000	609,000
deferred tax assets, net of current portion																																																															8,570,000	8,674,000	8,674,000	8,556,000
income taxes payable																																																															237,000	272,000	98,000	5,644,000	1,057,000	1,829,000	1,033,000	6,111,000	3,987,000	5,216,000	3,450,000	3,497,000	3,296,000
restricted cash																																																																						2,999,000	3,000,000	3,000,000	6,152,000	6,152,000	5,313,000	2,313,000	2,313,000	2,313,000	2,313,000	2,313,000	2,313,000	2,313,000	2,313,000	2,313,000	2,313,000
restricted cash, net of current portion																																																																					3,152,000	3,152,000	3,152,000	3,152,000
current portion of notes payable																																																																							3,227,000	3,968,000	3,888,000	3,795,000	3,705,000	3,617,000	3,295,000	3,217,000	3,046,000	2,721,000	2,006,000
notes payable, net of current portion																																																																							719,000	938,000	1,955,000	2,963,000	3,946,000	4,906,000	5,065,000	5,919,000	6,437,000	6,334,000	5,320,000
deferred stock-based compensation
deferred stock compensation																																																																												-22,000	-53,000	-89,000	-135,000	-932,000	-1,611,000	-2,460,000	-2,857,000	-2,941,000	-3,125,000	-3,697,000
related party notes receivable																																																																																		146,000	283,000	281,000	297,000	310,000
intangible assets, net of accumulated amortization of 1,454 and 1,143 at september 30, 2006 and december 31, 2005, respectively																																																																															2,180,000
intangible assets, net of accumulated amortization of 1,350 and 1,143 at june 30, 2006 and december 31, 2005, respectively																																																																																2,284,000
intangible assets, net of accumulated amortization of 1,247 and 1,143 at march 31, 2006 and december 31, 2005, respectively																																																																																	2,387,000
current portion of note payable																																																																																		1,876,000	1,765,000	1,776,000	1,288,000	790,000	379,000
note payable, net of current portion																																																																																		5,519,000	5,782,000	6,187,000	6,478,000	6,411,000	6,591,000	5,705,000
collaboration receivable																																																																																			304,000		1,867,000	859,000	916,000	3,000,000
intangible assets, net of accumulated amortization of 1,025 and 670 at september 30, 2005 and december 31, 2004, respectively																																																																																			3,050,000
accrued liabilities																																																																																			2,986,000	4,243,000	1,678,000	3,875,000	3,740,000	5,443,000
collaboration and license receivables																																																																																				679,000
intangible assets, net of accumulated amortization of 907 and 670 at june 30, 2005 and december 31, 2004, respectively																																																																																				3,168,000
intangible assets, net of accumulated amortization of 788 and 670 at march 31, 2005 and december 31, 2004, respectively																																																																																					3,287,000
liabilities, redeemable convertible preferred stock and stockholders’ equity
redeemable convertible preferred stock
deferred financing costs																																																																																							542,000	571,000
deferred compensation																																																																																							-4,359,000	-6,125,000
total liabilities, redeemable convertible preferred stock and stockholders’ equity																																																																																							62,545,000	68,473,000
current assets
current liabilities

Cashflow Statements:

Quarterly

Annual

Unit: USD	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30

cash flows from operating activities:
net income	205,991,000	186,419,000																																																							-11,368,000			-13,824,000	-16,285,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	13,553,000	13,506,000	13,803,000	13,944,000	14,405,000	14,168,000	13,982,000	15,003,000	13,517,000	13,482,000	13,328,000	13,179,000	14,065,000	14,311,000	10,600,000	10,097,000	9,460,000	11,375,000	11,786,000	11,805,000	12,601,000	10,386,000	8,573,000	8,200,000	7,613,000	5,442,000							3,178,000	3,714,000	3,587,000	3,066,000	3,000,000	3,018,000	3,500,000	4,011,000	4,601,000	5,069,000	5,270,000	5,021,000	3,690,000	3,341,000	3,117,000	2,868,000	2,600,000	2,627,000	2,764,000	2,711,000	2,127,000	2,024,000	2,285,000	2,605,000	2,121,000	1,237,000	1,262,000	1,287,000	1,339,000	1,291,000	1,266,000	1,223,000	1,161,000	1,136,000	1,111,000	1,943,000	1,802,000	1,798,000	1,631,000	1,346,000	951,000	902,000	1,048,000	937,000	1,195,000	1,087,000	992,000	947,000	789,000	752,000	740,000	952,000	675,000		728,000
non-cash interest expense on liabilities related to the sale of future royalties and development funding	66,236,000
stock-based compensation expense	70,154,000	71,632,000	108,211,000				45,804,000	89,288,000	45,347,000
realized and unrealized loss on marketable equity securities		0	0				1,567,000	1,367,000	-78,000	-767,000	16,844,000	-1,400,000	2,267,000	-6,796,000	7,850,000	1,097,000	31,161,000
deferred income taxes	9,310,000	-27,170,000	5,598,000	9,735,000	9,639,000																																																									10,875,000	11,000	-13,000	-131,000	-5,194,000	281,000	-13,000	-237,000
other	2,994,000	1,706,000	6,400,000	-18,510,000	-19,354,000	-6,760,000	-16,863,000	-10,177,000	-5,188,000	-14,655,000	23,340,000	-1,976,000	-6,276,000	-20,128,000	-42,915,000	42,345,000	21,177,000	22,454,000	2,870,000	1,575,000	30,777,000	9,631,000	-2,744,000	3,712,000	660,000	1,224,000	-5,201,000							0	0	0	608,000
changes in operating assets and liabilities:
accounts receivable	-110,421,000	184,247,000	-399,863,000	-136,913,000	-7,434,000	-59,508,000	-37,092,000	9,640,000	410,000	3,869,000	-107,991,000	-2,970,000	19,153,000	-53,269,000	-38,423,000	6,399,000	39,696,000	-59,449,000	3,670,000	-35,311,000	-10,709,000	-21,166,000	-8,971,000	6,783,000	-32,882,000	5,479,000	-17,783,000	3,107,000	-15,041,000	-15,398,000
inventory	-3,324,000	-13,861,000	4,976,000	11,144,000	6,215,000	849,000	5,925,000	6,794,000	22,000	11,990,000	4,795,000	1,985,000	-403,000	-18,978,000	-7,884,000	-9,200,000	1,926,000	-10,760,000	-13,634,000	-3,955,000	1,934,000	-8,464,000	-2,784,000	-12,226,000	-11,952,000	-4,316,000	-13,055,000	-7,906,000	-7,134,000	-12,291,000
prepaid expenses and other assets	-6,323,000	-70,990,000	-20,742,000	6,777,000	-32,769,000	25,281,000	-8,277,000	61,687,000	-75,462,000	23,398,000	-3,318,000	-27,874,000	-1,235,000	8,687,000	3,965,000	-21,307,000	-29,852,000	16,672,000	-18,144,000	-16,967,000	-13,654,000	11,465,000	17,325,000	6,398,000	-19,958,000	-8,380,000	-18,525,000	14,281,000	-9,418,000	-942,000	-12,864,000	6,279,000	-27,540,000	-18,659,000	-1,854,000	-3,906,000	3,708,000	-2,463,000	2,780,000	-3,583,000	-2,010,000	606,000	-2,336,000	-1,911,000	-3,179,000	960,000	-429,000	-1,861,000	-4,499,000	866,000	-572,000	-706,000	-944,000	3,139,000	1,254,000	319,000	-2,932,000	751,000	168,000	-158,000	1,970,000	-457,000	-411,000	-912,000	-958,000	1,022,000	154,000	127,000	-780,000	-151,000	-341,000	-2,260,000	1,004,000	1,198,000	-5,732,000	-480,000	666,000	-438,000	490,000	-467,000	79,000
accounts payable, accrued expenses and other liabilities	-176,033,000	-174,854,000	223,509,000	182,148,000	-155,737,000	-62,107,000	83,595,000	74,470,000	-4,865,000	-38,666,000	118,740,000	82,741,000	-81,975,000	102,617,000	69,745,000	68,143,000	-48,736,000	39,502,000	46,364,000	68,947,000	-66,573,000	68,168,000	73,528,000	16,251,000	-14,215,000
deferred revenue	-1,633,000	2,305,000	-12,540,000	-13,079,000	-27,321,000	-16,564,000	624,000	-190,943,000	-28,563,000	17,689,000	24,467,000	21,716,000	-8,850,000	-41,279,000	-12,465,000	158,000	-12,325,000	9,690,000	-8,352,000	-23,938,000	-27,804,000	-28,041,000	-8,834,000	-3,060,000	-4,030,000	-7,333,000	411,000	400,007,000	-834,000	-1,113,000	-8,616,000	-29,848,000	26,961,000	7,892,000	-4,985,000	-931,000	-128,000	5,951,000	3,286,000	2,799,000	2,579,000	2,668,000	3,374,000	2,051,000	-6,189,000	16,556,000	-9,252,000	-7,245,000	-7,845,000	753,000	-5,859,000	-8,332,000	7,237,000	16,106,000	12,732,000	-17,331,000	-20,069,000	-19,684,000	-20,306,000	-20,367,000	-9,898,000	-19,828,000	-22,122,000	-19,083,000	328,000	-20,284,000	-20,142,000	-19,259,000	1,513,000	-19,504,000	-185,000	99,412,000	-13,054,000	-15,122,000	265,102,000	-2,608,000	-2,376,000	-1,469,000	3,113,000	-2,172,000	-2,376,000	15,748,000	112,000	-373,000	270,000		567,000
net cash from operating activities	70,504,000	163,555,000	325,109,000	153,730,000	-118,314,000	-94,662,000	43,707,000	124,158,000	-81,515,000	-29,795,000	359,412,000	-58,986,000	-166,475,000	-131,978,000	-115,284,000	-122,819,000	-171,193,000	-150,141,000	-134,036,000	-121,856,000	-235,660,000	-123,144,000	-110,326,000	-135,330,000	-246,161,000	-195,980,000	-182,632,000	288,695,000	-188,510,000	-150,457,000	-153,808,000	-102,687,000	-155,664,000	-103,044,000	-98,363,000	-81,049,000	-100,330,000	-78,337,000	-75,536,000	-70,205,000	-83,623,000	-53,064,000	-54,365,000	-55,456,000	-26,255,000	-36,635,000	-40,706,000	-46,625,000	-41,675,000	-22,369,000	-21,715,000	-23,602,000	-971,000	-68,912,000	5,212,000	-21,694,000	-30,215,000	-25,159,000	-29,025,000	-26,579,000	-6,305,000	-20,388,000	-24,038,000	-24,314,000	-15,601,000	-16,869,000	-20,588,000	-35,919,000	1,231,000	-4,849,000	-16,010,000	95,008,000	-8,658,000	-8,438,000	224,309,000	-8,391,000	-10,961,000	-4,613,000	-2,932,000	-8,382,000	-8,703,000	3,616,000	-6,212,000	-6,250,000	-7,639,000	-1,016,000	-3,612,000
capital expenditures	-21,833,000	-23,292,000	-12,142,000	-14,293,000	-8,970,000	-9,094,000	-4,192,000	-8,018,000	-12,973,000	-15,309,000	-17,092,000	-15,919,000	-13,891,000	-21,635,000	-16,510,000	-16,055,000	-17,859,000	-21,886,000	-26,062,000	-11,246,000	-17,178,000	-21,668,000	-12,418,000	-16,658,000	-19,617,000	-38,805,000	-36,058,000	-21,244,000	-44,049,000	-37,513,000	-45,409,000	-22,708,000	-21,257,000	-20,728,000	-25,678,000	-21,651,000	-36,152,000	0	-20,298,000	-21,621,000	-2,759,000	-3,099,000	-6,477,000	-1,264,000	-2,110,000	-3,526,000	-3,195,000	-1,852,000	-388,000	-878,000	-950,000	-379,000	-1,799,000	-686,000	-5,729,000	-1,670,000	-263,000	-524,000	-265,000	-474,000	-28,000	-1,138,000	-1,067,000	-1,430,000	-1,097,000	-1,265,000	-737,000	-1,062,000	-1,885,000	-1,284,000	-2,282,000	-4,253,000	-2,945,000	-4,234,000	-705,000	-1,495,000	-1,354,000	-291,000	-746,000	-2,465,000	-1,484,000	-600,000	-372,000	-368,000	-607,000	-1,389,000	-1,179,000
free cash flows	48,671,000	140,263,000	312,967,000	139,437,000	-127,284,000	-103,756,000	39,515,000	116,140,000	-94,488,000	-45,104,000	342,320,000	-74,905,000	-180,366,000	-153,613,000	-131,794,000	-138,874,000	-189,052,000	-172,027,000	-160,098,000	-133,102,000	-252,838,000	-144,812,000	-122,744,000	-151,988,000	-265,778,000	-234,785,000	-218,690,000	267,451,000	-232,559,000	-187,970,000	-199,217,000	-125,395,000	-176,921,000	-123,772,000	-124,041,000	-102,700,000	-136,482,000	-78,337,000	-95,834,000	-91,826,000	-86,382,000	-56,163,000	-60,842,000	-56,720,000	-28,365,000	-40,161,000	-43,901,000	-48,477,000	-42,063,000	-23,247,000	-22,665,000	-23,981,000	-2,770,000	-69,598,000	-517,000	-23,364,000	-30,478,000	-25,683,000	-29,290,000	-27,053,000	-6,333,000	-21,526,000	-25,105,000	-25,744,000	-16,698,000	-18,134,000	-21,325,000	-36,981,000	-654,000	-6,133,000	-18,292,000	90,755,000	-11,603,000	-12,672,000	223,604,000	-9,886,000	-12,315,000	-4,904,000	-3,678,000	-10,847,000	-10,187,000	3,016,000	-6,584,000	-6,618,000	-8,246,000	-2,405,000	-4,791,000
cash flows from investing activities:
purchases of property, plant and equipment	-21,833,000	-23,292,000	-12,142,000	-14,293,000	-8,970,000	-9,094,000	-4,192,000	-8,018,000	-12,973,000	-15,309,000	-17,092,000	-15,919,000	-13,891,000	-21,635,000	-16,510,000	-16,055,000	-17,859,000	-21,886,000	-26,062,000	-11,246,000	-17,178,000	-21,668,000	-12,418,000	-16,658,000	-19,617,000	-38,805,000	-36,058,000	-21,244,000	-44,049,000	-37,513,000	-45,409,000	-22,708,000	-21,257,000	-20,728,000	-25,678,000	-21,651,000	-36,152,000
purchases of marketable securities	-261,625,000	-235,911,000	-207,971,000	-459,557,000	-401,642,000	-486,708,000	-430,377,000	-297,711,000	-420,115,000	-589,157,000	-421,457,000	-377,141,000	-435,746,000	-723,377,000	-157,309,000	-461,570,000	-634,705,000	-682,968,000	-458,331,000	-168,861,000	-345,954,000												-358,433,000	-391,431,000	-274,842,000	-150,381,000	-86,803,000	-143,647,000	-257,671,000	-193,431,000	-164,561,000	-135,802,000	-80,371,000	-310,053,000	-507,617,000	-125,102,000	-84,163,000	-280,912,000	-487,598,000	-29,108,000	-60,769,000	-87,351,000	-187,077,000	-81,457,000	-38,568,000	-38,894,000	-118,210,000	-75,294,000	-54,062,000	-121,969,000	-41,790,000	-102,980,000	-105,417,000	-100,965,000	-81,111,000	-81,396,000	-131,955,000	-174,301,000	-93,687,000	-88,952,000	-109,756,000	-181,847,000	-101,689,000	-188,130,000	-227,573,000	-30,798,000	-97,893,000	-53,505,000	-56,151,000	-37,408,000	-25,239,000	-51,697,000	-4,799,000	-6,430,000	-7,956,000	-856,000	-17,186,000
sales and maturities of marketable securities	213,191,000	222,037,000	723,370,000	332,469,000	524,381,000	443,009,000	423,519,000	339,669,000	365,468,000	363,810,000	432,223,000	384,347,000	373,420,000	604,720,000	492,710,000	628,918,000	505,220,000	291,450,000	396,122,000	337,296,000	438,682,000	500,955,000	331,360,000	319,740,000	539,614,000		607,050,000	309,409,000	403,697,000	398,138,000	491,181,000	384,508,000	244,876,000	131,571,000	163,342,000	104,361,000	198,031,000	263,917,000	246,564,000	311,660,000	294,317,000	218,357,000	135,518,000	204,381,000	168,687,000	150,063,000	125,264,000	54,389,000	133,206,000	86,034,000	59,215,000	34,521,000	58,036,000	125,656,000	62,150,000	48,165,000	53,042,000	96,602,000	90,578,000	125,080,000	64,105,000	151,697,000	111,168,000	75,432,000	74,746,000	138,280,000	102,738,000	126,854,000	136,698,000	93,635,000	75,687,000	136,844,000	204,878,000
proceeds from maturity of restricted and other investments	48,825,000
purchases of restricted and other investments	-4,100,000
net cash from investing activities	-25,542,000	-37,166,000	501,107,000	-141,381,000	113,769,000	-52,910,000	-30,250,000	33,940,000	-67,620,000	-240,656,000	-10,764,000	-8,713,000	-76,217,000	-139,911,000	313,891,000	142,793,000	-147,419,000	-413,405,000	-88,271,000	157,024,000	71,352,000	-97,888,000	-10,088,000	-441,230,000	113,688,000	-220,850,000	-10,077,000	-289,402,000	102,652,000	248,964,000	96,174,000	62,621,000	-134,814,000	-160,588,000	-137,178,000	-67,671,000	75,076,000	100,391,000	-31,405,000	-44,335,000	117,940,000	78,273,000	48,670,000	-106,936,000	-341,328,000	21,435,000	37,906,000	-228,375,000	-379,780,000	56,048,000	-2,504,000	-53,209,000	-130,840,000	43,513,000	17,853,000	7,601,000	-65,593,000	20,784,000	36,251,000	2,637,000	22,287,000	47,579,000	4,684,000	-26,963,000	-7,462,000	55,619,000	-29,954,000	-45,357,000	34,125,000	3,399,000	-36,451,000	-49,256,000	100,244,000	-87,688,000	-165,889,000	26,004,000	-49,852,000	-4,839,000	2,119,000	-14,616,000	-12,710,000	-47,214,000	4,474,000	3,230,000	-908,000	918,000	-14,935,000
cash flows from financing activities:
proceeds from exercise of stock options and other types of equity	13,157,000	41,701,000	77,740,000	81,222,000	49,365,000	36,278,000	108,036,000	132,778,000	25,859,000	30,894,000	24,805,000	49,394,000	42,371,000	56,714,000	153,020,000	22,503,000	27,123,000	45,041,000	72,389,000	81,861,000	46,977,000	19,025,000	29,947,000	97,643,000	53,869,000	40,342,000	9,217,000	12,642,000	9,083,000	7,671,000	13,533,000	5,641,000	42,094,000	42,542,000	28,956,000	9,875,000	2,769,000	3,437,000	4,424,000	4,442,000	1,824,000	6,543,000	3,831,000	7,197,000	13,566,000	7,685,000	5,056,000	5,138,000	11,541,000	8,924,000	11,199,000	3,982,000	4,638,000	997,000	4,499,000	628,000	847,000
proceeds from liabilities related to the sale of future royalties and development funding	6,000,000
repayment of liabilities related to the sale of future royalties and development funding	-3,434,000
other financing activities	-9,000
net cash from financing activities	15,714,000			53,757,000	44,084,000	30,997,000	102,755,000	131,496,000	28,911,000	39,228,000	33,138,000	53,394,000	46,371,000	63,437,000	297,023,000	30,337,000	34,956,000	292,291,000	573,839,000	329,811,000	51,177,000	217,950,000	34,147,000	689,013,000	53,869,000	40,342,000	-20,699,000	412,610,000	390,931,000	5,378,000	12,989,000	5,581,000	41,522,000	706,948,000	28,915,000	386,312,000	2,716,000	3,082,000	4,346,000	154,338,000	16,066,000	6,468,000	3,651,000	7,074,000	598,984,000	7,658,000	4,794,000	5,138,000	718,875,000	7,650,000	11,084,000	3,982,000	178,210,000	966,000	4,499,000	628,000	87,319,000	267,000	0	462,000	9,000	527,000	53,000	2,541,000	542,000	635,000	763,000	1,901,000	210,000	-3,484,000	1,607,000	5,504,000	-472,000	755,000	57,973,000	303,000	-396,000	101,696,000	617,000	1,836,000	62,482,000	52,151,000	-343,000	207,000	602,000	5,528,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	-7,064,000	-5,701,000	-927,000	27,506,000	14,058,000	-17,271,000	15,093,000	-3,120,000	-9,941,000	10,897,000	-6,552,000	-130,000	2,176,000	1,619,000	2,024,000	-8,835,000	-2,238,000	-3,050,000	-3,139,000	1,081,000	-3,910,000	2,972,000	2,142,000	435,000	-631,000	366,000	-446,000
net increase in cash, cash equivalents and restricted cash	53,612,000	166,005,000	376,941,000	93,612,000	53,597,000	-133,846,000	131,305,000			-220,326,000				-206,833,000				-274,305,000	348,393,000			-110,000	-84,125,000	112,888,000	-79,235,000	-376,122,000	-213,854,000	411,900,000	305,073,000	103,885,000	-44,645,000
cash, cash equivalents and restricted cash, beginning of period	1,658,807,000	0	0	0	968,652,000	0	0	0	814,884,000	0	0	0	868,556,000	0	0	0	822,153,000	0	0	0	499,046,000	0	0	0	549,628,000	0	0	0	422,631,000	0	0	0	646,832,000
cash, cash equivalents and restricted cash, end of period	1,712,419,000	166,005,000	376,941,000	93,612,000	1,022,249,000	-133,846,000	131,305,000	286,474,000	684,719,000	-220,326,000	375,234,000	-14,435,000	674,411,000	-206,833,000	497,654,000	41,476,000	536,259,000	-274,305,000	348,393,000	366,060,000	382,005,000	-110,000	-84,125,000	112,888,000	470,393,000	-376,122,000	-213,854,000	411,900,000	727,704,000	103,885,000	-44,645,000	-34,485,000	397,876,000
supplemental disclosure of cash flows:
cash paid for interest	64,200,000	113,317,000	23,893,000	14,564,000	66,933,000	12,330,000	16,147,000	8,156,000	30,945,000	5,443,000	9,547,000	3,216,000	13,912,000	1,303,000	14,872,000																																																																	159,000	161,000		181,000	143,000	135,000		108,000
cash paid for taxes	2,369,000		1,277,000	-1,871,000	2,969,000
operating lease right-of-use assets obtained in exchange for new operating lease liabilities		8,816,000	3,842,000	-1,289,000	9,826,000
supplemental disclosure of noncash investing activities:
capital expenditures included in accounts payable and accrued expenses	9,185,000	1,298,000	5,523,000	431,000	3,650,000					-1,349,000	-509,000	1,629,000	4,034,000			-1,800,000	8,318,000	4,185,000	-2,382,000	4,507,000	7,289,000	7,470,000	646,000	-217,000	6,619,000	-4,047,000	-6,970,000	12,860,000	13,033,000
loss related to convertible debt
change in fair value of development derivative liability			64,663,000	15,259,000	58,891,000	70,271,000	36,271,000	55,642,000	8,586,000	23,102,000	31,209,000	30,215,000	6,471,000	23,883,000
proceeds from maturity of restricted investments		0	1,700,000	9,250,000	48,825,000	0	0	17,900,000	39,975,000	0	0	9,250,000	49,225,000	0			9,400,000	16,000,000	15,325,000	0	10,650,000					0
purchases of restricted investments		0	-1,700,000	-9,250,000	-48,825,000	0	-19,200,000	-17,900,000	-39,975,000	0	0	-9,250,000	-49,225,000	0			-9,400,000	-16,001,000	-15,325,000	-165,000	-10,650,000	-16,000,000	0	0	-9,900,000					0	0
other investing activities		0								0				381,000	3,500,000	-8,500,000	-75,000	0	0	0	-4,198,000		0
proceeds from issuance of 0.00% convertible senior notes due 2028		-680,000
purchases of capped calls related to 0.00% convertible senior notes due 2028		0
repayment of 1.00% convertible senior notes due 2027		-52,254,000
payment of issuance costs for revolving credit agreement		0
(repayment of) proceeds from development derivative liability
non-cash interest expense on liability related to the sale of future royalties			40,864,000	36,472,000	34,962,000	35,299,000	30,731,000	29,538,000	31,565,000	27,636,000	27,271,000	26,372,000	25,275,000	24,579,000	24,917,000	27,002,000	27,702,000	29,365,000	30,177,000	28,836,000	28,184,000	28,517,000
loss on extinguishment of debt														0
(repayment of) proceeds from development derivative			-32,076,000	-27,465,000	-5,281,000
net cash from (provided by) financing activities
net loss				-66,277,000	-57,479,000	-83,763,000	-111,570,000	-16,889,000	-65,935,000	-137,870,000	147,753,000	-276,024,000	-174,101,000	-207,493,000	-405,920,000	-277,402,000	-240,341,000	-258,460,000	-204,514,000	-189,559,000	-200,291,000	-243,540,000	-253,291,000	-179,229,000	-182,221,000	-276,185,000	-208,535,000	-219,481,000	-181,915,000	-211,441,000	-245,282,000	-163,560,000	-141,214,000	-142,227,000	-122,937,000	-118,420,000	-107,290,000	-112,934,000	-104,071,000	-90,129,000	-102,974,000	-90,721,000	-76,792,000	-71,783,000	-50,777,000	-21,389,000	-43,989,000	-44,074,000	-250,943,000	-32,357,000	-29,686,000	-18,169,000	-9,013,000	-62,188,000	-19,502,000			-14,303,000					-9,630,000	-14,632,000	-12,323,000	-7,791,000	-9,208,000	-22,702,000	-7,889,000	-9,392,000	-2,858,000	-12,760,000	-1,239,000	1,662,000	-52,792,000	-12,691,000	-21,645,000	-8,438,000	-7,400,000	-9,910,000	-8,860,000	-14,491,000	-10,678,000	-11,145,000	-6,600,000	-5,700,000	-6,416,000
adjustments to reconcile net loss to net cash from operating activities:
non-cash adjustments to reconcile net loss to net cash from operating activities:
stock-based compensation					56,712,000					41,994,000	63,937,000	75,802,000	39,947,000	42,767,000	128,118,000	30,471,000	29,293,000	44,582,000	33,367,000	32,078,000	55,690,000	34,276,000	37,264,000	33,755,000	34,578,000	66,197,000	46,009,000	30,603,000	32,032,000	27,973,000	87,954,000	22,241,000	19,584,000	27,117,000	25,955,000																																																			-2,292,000	731,000
unrealized loss on marketable equity securities					956,000
realized and unrealized losses on marketable equity securities
proceeds from convertible debt														-777,000
purchases of capped calls related to convertible debt														0
repayment of term loan facility
cash paid for income taxes
amortization and interest accretion related to operating leases							13,056,000	9,689,000	11,969,000	10,491,000	10,204,000	10,268,000	12,014,000	10,574,000	10,050,000	10,140,000	10,318,000	10,076,000	11,434,000	10,356,000	10,261,000	10,494,000	10,198,000	9,578,000	9,393,000	9,320,000
operating lease liability							-14,046,000	-10,951,000	-12,840,000	-11,488,000	-11,167,000	-11,020,000	-12,827,000	-11,453,000	-10,284,000	-10,762,000	-10,672,000	-10,766,000	-10,369,000	-10,157,000	-9,060,000	-10,314,000	-13,037,000	-9,199,000	-9,036,000
proceeds from development derivative								-1,282,000	3,052,000	8,334,000	8,333,000	4,000,000	4,000,000	7,500,000	7,833,000	7,834,000	7,833,000	3,500,000	7,700,000	4,200,000	4,200,000	4,200,000
net decrease in cash, cash equivalents and restricted cash									-130,165,000			-14,435,000	-194,145,000			41,476,000	-285,894,000				-117,041,000												-248,956,000
proceeds from the sale of future royalties																		0				0	0
(repayment of) proceeds from term loan facility
repayment of term loan														0												0
proceeds from term loan facility																		250,000,000	0
proceeds from issuance of common stock to strategic partners, net of closing costs																						0	0
supplemental disclosure of noncash investing and financing activities:
lease liabilities arising from obtaining right-of-use assets																		56,000	2,567,000			72,000	19,286,000	12,138,000	2,939,000
receivable and liability related to the sale of future royalties																						0	0
realized and unrealized gain on marketable equity securities																		5,578,000	-18,691,000	4,434,000	-47,016,000	12,584,000
offering proceeds, net of costs																										0	0	0	381,900,000
payment of transaction costs related to sale of future royalties and term loan facility																			-6,250,000				0
change in fair value of liability obligation																										0	0
gain on litigation settlement
proceeds from landlord lease incentive for tenant improvements																						2,860,000	699,000			1,106,000	10,364,000	6,314,000	12,386,000	13,753,000	7,117,000
proceeds from issuance of term loan
payment of transaction costs related to sale of future royalties and term loan
purchases of marketable debt securities																							-329,030,000	-744,012,000	-396,409,000	-630,293,000	-611,069,000	-577,567,000	-256,996,000	-111,661,000	-349,598,000
proceeds from public offering, net of costs
non-cash imputed interest expense on liability related to the sale of future royalties
unrealized gain on marketable equity securities																								-45,532,000	-24,111,000						-2,960,000
fair value adjustments on marketable equity securities																												0	-21,000
accounts payable, accrued expenses and other
sales and maturities of marketable debt securities
proceeds from issuance of common stock to sanofi genzyme																																		0	0			0	0	0	14,301,000
proceeds from issuance of common stock to regeneron																										0	0
charge for 401(k) company stock match																											1,178,000	1,001,000	1,089,000	-453,000	1,286,000	1,384,000	942,000	567,000	661,000	523,000	551,000	305,000	421,000	450,000	331,000	209,000	254,000	274,000	247,000	179,000	181,000	175,000	157,000	98,000	104,000	127,000	120,000	54,000	98,000	116,000	96,000	95,000	119,000	136,000	138,000	93,000	131,000	138,000	133,000	96,000	116,000	124,000	125,000	90,000	100,000	102,000	90,000	203,000	65,000	74,000	65,000	38,000	46,000
accounts payable																											-30,088,000	43,502,000	-17,133,000	16,128,000	9,085,000	-693,000	-9,042,000	12,332,000	-8,945,000	2,741,000	-11,067,000	11,560,000	2,128,000	-3,937,000	347,000	2,561,000	310,000	-1,945,000	750,000	9,666,000	-947,000	1,500,000	-1,379,000	3,168,000	-1,806,000	1,429,000	-959,000	-1,029,000	-426,000	1,180,000	-1,461,000	314,000	-2,463,000	2,149,000	-3,512,000	2,751,000	-3,837,000	3,410,000	-5,501,000	4,063,000	1,963,000	-2,266,000	6,141,000	-754,000	-2,898,000	-2,844,000	5,258,000	-3,232,000	1,385,000	2,662,000	-1,079,000	1,619,000	-1,243,000	-235,000	1,947,000	-63,000	373,000	-37,000	752,000		-348,000
accrued expenses and other liabilities
depreciation, amortization and accretion																												9,745,000	12,210,000	-2,228,000	3,246,000
non-cash gain on litigation settlement																														0	0
accrued expenses and other																												16,158,000	-14,731,000	34,115,000	17,981,000	19,028,000	-11,767,000	25,578,000	9,394,000	7,451,000	-10,855,000	3,924,000	5,032,000	6,022,000	-4,305,000	10,818,000	2,434,000	1,523,000	-8,432,000	1,831,000	5,056,000	-1,538,000	3,773,000	-2,324,000	6,914,000	-1,253,000	-1,790,000	-6,269,000	91,000	2,335,000	252,000	716,000	831,000	-870,000	1,780,000	98,000	3,123,000	-1,362,000	-1,208,000	1,420,000	-1,560,000	-872,000	671,000	-858,000	35,000	-593,000	-2,405,000
payments for repurchase of common stock for employee tax withholding																												-32,000	-52,000	-2,293,000	-544,000	-60,000	-572,000	-69,000	-41,000	-94,000	-53,000	-355,000	-78,000	-104,000	-59,000	-75,000	-180,000			-27,000	-262,000	0	-15,703,000	-1,274,000				-31,000	0	0	-328,000
sale of restricted investments
proceeds from issuance of common stock, net of offering costs																																		784,475,000	0							0	0	0	496,400,000					0	0	0	173,572,000	0	0	0	86,800,000
proceeds from issuance of long-term debt																																						0	0
repayment of long-term debt
fair value of common stock received in the period for collaboration agreement in other assets
receipt of common stock for exercises of stock options
repurchase of common stock for employee tax withholding in accrued expenses
realized loss on sale of marketable equity securities																																		0	0	345,000	1,549,000
billed and unbilled collaboration receivables																																47,807,000	-16,766,000	-19,358,000	761,000	4,052,000	3,877,000	-8,188,000	-5,632,000	-700,000	-516,000	-168,000	1,273,000	704,000	29,830,000	-39,553,000	-295,000	75,000	4,084,000	-3,639,000	-149,000	98,000	-454,000	1,814,000	2,467,000	-2,193,000	-724,000
proceeds from landlord tenant improvements																																						0												12,000	0	0	192,000	566,000
purchases of restricted investments and increase in restricted cash																																						0
net increase in cash and cash equivalents																																		443,316,000	-206,626,000	237,592,000	-22,538,000	25,136,000	-102,595,000	39,798,000	50,383,000	31,677,000	-2,044,000	-155,318,000	231,401,000	-7,542,000	1,994,000	-269,862,000	297,420,000	41,329,000			46,399,000		27,564,000	-13,465,000	-8,489,000				15,991,000				-22,521,000	39,381,000	-49,783,000	-79,398,000	35,476,000	-4,945,000	-50,799,000	51,255,000	91,124,000	-95,390,000	116,083,000	17,802,000	-61,293,000	92,439,000	-129,000	-21,159,000	41,047,000						-17,347,000
cash and cash equivalents, beginning of period																																		0	0	0	193,617,000	0	0	0	180,895,000	0	0	0	75,179,000	0	0	0	53,169,000	0	0	0	51,405,000	0	0	0	70,228,000	0	0	0	74,599,000	0	0	0	137,468,000	0	0	0	191,792,000	0	0	0	105,157,000	0	0	0	127,955,000	0	0	0	15,757,000	0	0	0	20,272,000		0
cash and cash equivalents, end of period																																		443,316,000	-206,626,000	237,592,000	171,079,000	25,136,000	-102,595,000	39,798,000	231,278,000	31,677,000	-2,044,000	-155,318,000	306,580,000	-7,542,000	1,994,000	-269,862,000	350,589,000	41,329,000	-13,135,000	-72,829,000	97,804,000	-24,433,000	27,564,000	-13,465,000	61,739,000	-4,108,000	7,226,000	-23,480,000	90,590,000	27,718,000	-19,301,000	-48,765,000	114,947,000	39,381,000	-49,783,000	-79,398,000	227,268,000	-4,945,000	-50,799,000	51,255,000	196,281,000	-95,390,000	116,083,000	17,802,000	66,662,000	92,439,000	-129,000	-21,159,000	56,804,000	8,579,000	-1,987,000	-3,050,000	12,215,000		-17,347,000
fixed asset expenditures included in accounts payable and accrued expenses																																																					245,000
fair value of common stock received for collaboration agreement in other assets
non-cash stock-based compensation																																					15,717,000	20,651,000	15,581,000	15,816,000	23,480,000	15,520,000	11,848,000	10,179,000	8,236,000	13,438,000	6,352,000	7,680,000	5,591,000	5,406,000	8,845,000	3,377,000	3,075,000	2,722,000	3,386,000	3,096,000	3,156,000	4,082,000	4,258,000	4,214,000	4,122,000	4,212,000	4,511,000	5,068,000	5,327,000	3,940,000	5,634,000	5,417,000	4,736,000	4,123,000	5,017,000	4,882,000	4,004,000	2,604,000	7,922,000	1,786,000	2,160,000	2,609,000	1,714,000	1,606,000	2,375,000	1,002,000	2,196,000	919,000	480,000
deposit for manufacturing facility																																									-9,057,000
realized gain on sale of marketable securities																																						-161,000	-706,000	-954,000	-5,156,000					-1,514,000								-76,000	0	-4,000	-175,000
benefit from intraperiod tax allocation																																													-431,000	-22,091,000	67,000	-315,000	-17,870,000
in-process research and development																																														0	0	-3,890,000	224,656,000
payment for asset acquisition																																														0	0	0	-25,000,000
net cash paid for income taxes
fair value of common stock issued for asset acquisition
difference in fair value of common stock issued to sanofi genzyme less cash proceeds received
purchases of property and equipment																																							-20,298,000	-21,621,000	-2,759,000	-3,099,000	-6,477,000	-1,264,000	-2,110,000	-3,526,000	-3,195,000	-1,852,000	-388,000	-878,000	-950,000	-379,000	-1,799,000	-686,000	-5,729,000	-1,670,000	-263,000	-524,000	-265,000	-474,000	-28,000	-1,138,000	-1,067,000	-1,430,000	-1,097,000	-1,265,000	-737,000	-1,062,000	-1,885,000	-1,284,000	-2,282,000	-4,253,000	-2,945,000	-4,234,000	-705,000	-1,495,000	-1,354,000	-291,000	-746,000	-2,465,000	-1,484,000	-600,000	-372,000	-368,000	-607,000	-1,389,000	-1,179,000
purchases of restricted cash and investments
increase in restricted cash																																										-1,183,000	0	0	-288,000									0	0	0	-162,000
net (cash paid for income taxes) cash proceeds from income tax refunds
proceeds from issuance of common stock to genzyme																																											0	0	89,018,000	0	0	0	723,037,000
equity in loss of joint venture																																																						881,000	1,613,000	1,139,000	889,000	954,000	467,000	1,012,000	1,072,000	916,000	1,226,000	3,919,000	1,578,000	1,488,000	740,000	812,000	1,870,000	3,116,000	1,813,000	1,272,000	1,445,000	936,000
gain on issuance of stock by joint venture
net cash proceeds from income tax refunds
difference in fair value of common stock issued to genzyme less cash proceeds received
tax benefit from stock-based compensation
other than temporary impairment on equity securities																																																										0
benefit from intraperiod tax allocation on marketable securities																																																		3,021,000	-2,270,000	-2,884,000	-562,000
income taxes receivable																																																										0	0	0	10,669,000
cash (paid for income taxes) proceeds from income tax refunds
net decrease in cash and cash equivalents																																																										-4,108,000	7,226,000				-19,301,000																						-8,057,000
income taxes payable																																																														30,000	1,000	-1,000	-5,546,000	4,327,000	-512,000	796,000	-5,078,000	2,248,000	-855,000	1,268,000	-47,000	201,000
proceeds from issuance of shares to novartis																																																														0	0							0	0
effect of exchange rate on cash																																																														0	0			-4,000	-4,000	-23,000	-90,000	-11,000	55,000	-1,000	10,000	-19,000	-310,000	-114,000	-84,000	195,000	67,000	3,000	-22,000	26,000	94,000	-237,000	-112,000
(cash paid for income taxes) proceeds from income tax refunds
decrease in restricted cash																																																																		0	0	3,152,000	2,999,000																		0
investment in joint venture																																																																		0	0	0	-10,000,000	0
proceeds from issuance of common stock																																																										267,000	0	462,000	9,000	527,000	53,000	1,548,000	542,000	635,000	763,000	747,000	210,000		2,567,000													10,000	37,000
net proceeds from income tax refunds
collaboration receivables																																																											-719,000	-158,000	2,300,000	1,431,000	1,477,000	-1,853,000	1,539,000	-1,022,000	835,000	-26,000	-1,643,000	19,952,000	-19,014,000	4,554,000	-4,649,000	98,000	493,000	-1,221,000	-564,000	1,018,000	-1,256,000	-475,000	-2,507,000
non-cash income tax benefit
impairment on equity investment																																																																						0
repayments of notes payable																																																																						-3,946,000	-960,000	-937,000	-915,000	-892,000	-872,000	-794,000	-775,000	-734,000	-602,000	-477,000	-446,000
supplemental disclosure of cash flows
adjustments to reconcile net loss to net cash from (used in) operating activities:
non-cash license expense																																																																										0	0	0	7,909,000	0	0			0	0
disposals of property and equipment																																																																										-1,000
proceeds from notes payable																																																																										0	0			387,000	1,031,000	2,205,000	377,000
supplemental disclosure of non-cash financing activities
common stock issued in connection with license agreements
proceeds from landlord for tenant improvements																																																																							0				0				0
proceeds from issuance of common stock to novartis
deferred income tax provision																																																																						-5,517,000	-16,000	48,000	-16,000	0
proceeds from issuance of common stock, net of issuance costs																																																																									443,000	1,647,000	58,845,000	140,000	379,000	102,043,000	188,000	108,000	62,551,000	52,303,000
investment in regulus therapeutics llc
accrued expenses																																																																											1,645,000	2,679,000	2,815,000	-641,000	525,000	934,000	-207,000	946,000			-2,190,000		-1,085,000
deferred rent																																																																											-151,000	176,000	-107,000
sales of marketable securities																																																																											70,046,000	58,297,000	49,395,000	48,957,000	59,016,000	25,257,000	14,013,000	5,083,000	9,645,000	10,028,000	7,655,000	5,475,000	1,000,000
loss on disposal of equipment
realized foreign currency losses																																																																														115,000	49,000	72,000	19,000
changes in operating assets and liabilities, net of effects of acquisition:
proceeds from sale of equipment
proceeds from issuance of preferred stock, net of issuance costs
deferred financing costs incurred in connection with the equipment line of credit																																																																																							0
common stock issued to max planck innovation
fair value of warrant issued in connection with equipment line of credit included as deferred financing costs
conversion of redeemable convertible preferred stock into common stock																																																																																							0
accretion of redeemable convertible preferred stock																																																																																							0
deferred tax asset																																																																															38,000	37,000	38,000
changes in operating assets and liabilities
supplementary information:
series b preferred stock issued for garching license
charge for purchased in-process research and development
realized foreign currency
acquisition of ribopharma ag, net of cash acquired
proceeds from bank debt																																																																																					565,000
repayments of bank debt
repayment of debt assumed in acquisition
realized foreign currency exchange gains																																																																																			1,000
purchases from landlord reimbursement of tenant improvements
collaboration receivable																																																																																					-1,008,000		2,084,000
prepaid expenses and other current assets																																																																																			-65,000	-247,000	-18,000		60,000
proceeds from issuance of series d convertible preferred stock
proceeds from note payable																																																																																			0
repayments of note payable
deferred financing costs incurred in connection with note payable
gain on disposal of equipment
collaboration and license receivables
accrued liabilities
deferred financing costs incurred in connection with initial public offering
beneficial conversion feature on issuance of series d convertible preferred stock
general and administrative
compensation and related
consulting and professional services
facilities related
operating activities:
non-cash adjustments to net loss
tenant improvement reimbursements
investing activities:
financing activities:
issuances of common stock
issuances of preferred stock
proceeds from debt
repayments of debt
changes in restricted cash
deferred financing costs
increase in cash and cash equivalents
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
cash flows from operating activities
adjustments to reconcile net loss to net cash flows from operating activities:
loss on disposal of property and equipment
charge for purchased in-process r&d
changes in operating assets and liabilities; net of acquisition
cash flows from investing activities
proceeds from landlord reimbursement of tenant improvements
proceeds from the sale of equipment																																																																																							10,000
acquisition of ribopharma ag, net of acquired cash
cash flows from financing activities
proceeds from the issuance of common stock, net of issuance costs																																																																																							-88,000
proceeds from issuance of series a redeemable convertible preferred stock, net of issuance costs
proceeds from issuance of series b redeemable convertible preferred stock, net of issuance costs
proceeds from issuance of series c redeemable convertible preferred stock, net of issuance costs
repayment of bank debt																																																																																							0
repayment of debt assumed in ribopharma acquisition
effect of exchange rate changes on cash																																																																																							23,000
supplemental disclosure of noncash financing activities
fair value of warrants issued in connection with equipment line of credit included as deferred financing costs																																																																																							0
gain on disposal of property and equipment
proceeds from issuance of series d convertible preferred stock, net of issuance costs
proceeds of bank debt
deferred financing costs incurred in connection with the acquisition of ribopharma
net cash from (used by) financing activities

Alnylam Pharmaceuticals, Inc(NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc
(NASDAQ:ALNY)